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Chapter I 
Introduction 
1 CLINICAL ASPECTS 
1.1 Epidemiology and genetics 
Psoriasis is a common chronic disease of the skin, of complex heredity and unknown 
aetiology. It affects about 2% of the world's population, but may be less common 
among Eskimos, American Indians and Japanese.1 Previously it was thought to be 
transmitted as a dominant condition with uncomplete penetrance,2 but an association 
has been found between psoriasis and the HLA antigens and it has been concluded 
that the condition is determined by a number of genes (polygenic).3 In addition, it 
is generally accepted that the disease is precipitated by various non-genetic trig-
gering factors. These include trauma (Koebner phenomenon), stress, infections, 
hormones, drugs and hypocalcaemia* 
1.2 Cutaneous manifestations 
The morphology of the skin lesions varies considerably; the clinical presentation 
appears to depend on "the eruptive pressure"5 inherent to the disease, a culmination 
of exacerbating, perpetuating and remitting factors (Fig. 1). This pressure is variable 
and may cause in an individual a few localized psoriasis plaques, or generalized 
inflammation of the skin with the development of pustules. The variability in the 
expression of psoriasis is not only restricted to the different manifestations but this 
dynamic picture may even be observed within a single manifestation. Lesions are 
initiated, they grow and regress. At one extreme the dynamic cycle is relatively 
short (weeks or months) as in guttäte psoriasis; at the other extreme it can be 
chronic (months or years) as in chronic plaque psoriasis. 
1.2.1 Chronic plaque psoriasis 
This clinical manifestation is the most common and is characterized by sharply 
defined erythemato-squamous plaques varying in shape and size and covered with 
silver-white scales (Fig. 2). Areas of prediliction are the elbows, knees, scalp and 
sacral region. 
1.2.2 Guttäte psoriasis 
This is a less common erythemato-squamous form with small lesions (0.5-1.5 cm in 
diameter) appearing over the trunk and proximal extremities, particularly in children 
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and young adults and often after acute streptococcal infections. The prognosis is 
excellent in children, spontaneous remissions occur in the course of weeks or 
months. In adults the prognosis is poor. 
1.2.3 Erythrodermic psoriasis 
The typical features of psoriasis have been replaced by a generalized erythema and 
scaling. This pattern is not unique for psoriasis, but about 20% of all patients with 
erythroderma have underlying psoriasis. 
1.2.4 Generalized pustular psoriasis (GPP von Zumbush type) 
Pustular psoriasis is an acute variant of psoriasis and is far less common than the 
erythemato-squamous manifestation. Attacks of pustular psoriasis are accompanied 
by fever which lasts several days. Parallel to the onset of fever there occurs a sudden 
eruption of 2-3 mm sterile pustules on an erythematous skin. The pustules are dis-
simulated over the trunk and the extremities including the nailbed, palms and soles. 
Patients with a previous history of acrodermatitis continua of Hallopeau have an es-
pecially poor prognosis. The long-term course in patients with generalized pustular 
psoriasis is variable, periods with an erythemato-squamous manifestation may occur. 
1.2.5 Localized pustulosis of hand and feet 
The relationship of pustulosis of the palms and soles to psoriasis vulgaris is in 
debate.0 From a clinical point of view, division of this rare disorder in the fol-
lowing subtypes is useful. 
1.2.6 Persistent palmoplantar pustulosis (PPP) 
The clinical picture is characterized by erythematous plaques with varying amount 
of scaling and sterile pustules (Fig. 3). Lesions are most prominent on the thenar, 
hypothenar, soles and sides of the heels. The course is usually persistent. 
1.2.7 Acrodermatitis continua of Hallopeau 
This manifestation is expressed by sterile pustular eruption of the fingers and some-
times the toes, which slowly extends proximally. Continuous pustulation may cause 
nail-destruction, atrophy of the distal phalanx and arthropathy of the interpha-
langeal joints. As with PPP the disorder is very resistent to therapy. 
1.3 Extracutaneous manifestations 
Common extracutaneous manifestations are the nails, the mucosal membranes and 
the joints.4 
1.4 Histology 
The histological picture of the fully developed psoriatic lesion is best seen at the 
margin of enlarging plaques. It shows elongation of the rete ridges with thickening 
in their lower portions, long oedematous and often club-shaped papillae, thinning 
10 
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Fig. 1. Diagram showing the dynamics of psoriasis with related factors. 
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of the suprapapillary portion of the stratum Malpighii, absence of a granular layer, 
acanthosis, parakeratosis, increased mitotic figures in the basal and suprabasal 
cell-layer and as a characteristic feature accumulation of polymorphonuclear leuko­
cytes (PMN) in the epidermis.7 In the papillary dermis there is tortuosity and 
dilation of the capillaries and a mild mononuclear inflammatory infiltrate. In exacer­
bating lesions, some PMN can be seen. 
The infiltrate cells showing the most impressive penetration into the epidermis are 
the PMN. They migrate through the "squirting papillae"3, discontinuities of the 
basement membrane and in the stratum Malpighii they form the spongioform "micro-
pustules of Kogoj": aggregates of PMN within the interstices of a sponge-like 
network formed by degenerated and thinned epidermal cells (Fig. 4a). Subsequently 
they form the "microabscesses of Munro": accumulations of pyknotic nuclei of PMN 
in the horny layer (Fig. 4b). 
All pustular forms of psoriasis are mainly characterized by a spongiform pustule 
(Kogoj) with parakeratotic foci within the epidermis and a variable dense mono­
nuclear infiltrate intermingled with some PMN around dilated vessels in the oedema-
tous papillae. 
1.5 Therapy 
A permanent cure for psoriasis is not yet possible. Several "classical" therapies are 
available for its treatment, but their ultimate working mechanism is unknown. All 
available therapies have certain advantages and disadvantages for the patient. 
Topical treatment with potent corticosteroid is a practical approach, cosmetically 
acceptable and recommended for quick clearing. However, remission periods are 
usually short and long-term treatment includes the possibility of skin atrophy. 
Severe relapses may occur following discontinuation of this therapy. 
Treatment with dithranol (anthralin) is effective and safe, and results in prolonged 
remission periods. However, a careful dosage management is essential, necessitating 
visits to day-care centres or in some cases in-patient treatment. 
For widespread psoriasis phototherapy with ultraviolet В radiation or photochemo-
therapy (ultraviolet A radiation following ingestion or topical application of a psora­
len) is very effective. However, the cumulative carcinogenic potential of light ther­
apies dictate a restricted use of the treatment modalities. 
Systemic therapies with the cytotoxic agent methotrexate or aromatic retinoids are 
indispcnsible for recalcitrant forms of psoriasis. These therapies are especially useful 
in the treatment of pustular and erythrodermic psoriasis. Nevertheless, side-effects 
necessitate sustained supervision of the patient. 
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Fig. 2. Chronic plaque psoriasis. 
Fig. 3. Persistent palmoplantar pustulosis (PPP). 
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Fig. 4. Histopathology of a chronic plaque lesion (haematoxylin-eosin staining). 
(a) Micropustules of Kogoj in the stratum Malpighii. 
(b) Microabscesses of Munro in the stratum comeum. 
2 PATHOGENETIC ASPECTS 
2.1 Overview 
Systemic and local abnormalities have been suggested to be of relevance in the 
pathogenesis of psoriasis.9·10 The systemic processes include both non-cellular and 
cellular factors.11 At the cellular level nearly every type of cell in the lesion has 
been suspected of being responsible for the psoriatic changes: keratinocytes, mono­
cytes, Langerhans cells, Τ lymphocytes, mast cells, endothelial cells, fibroblast and 
PMN. Indeed in the fully developed psoriatic lesion both dermis and epidermis are 
abnormal. However, there is no consensus as to which of these cells are primarily 
responsible. A detailed account of these changes is given in the textbook of pso­
riasis.12 This thesis considers one cell type, the PMN. 
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2.2 The polymorphonuclear leukocytes (PMN) 
2.2.1 PMN in general 
The PMN with its characteristic multUobed nucleus is the most abundant of the 
granulocytes. Its primary function is the phagocytosis and killing of microorganisms, 
especially bacteria. The PMN contain azurophil and specific granules: its major con-
stituents are enzymes. These enzymes may be released following stimulation by a 
variety of agents.13 The enzyme elastase (EC 3.4.21.37) is one of the major neutral 
proteases present in the azurophilic granules. It is unique for the PMN and essential 
for its penetration into tissues in various disorders. In skin, Briggaman et al1"* have 
shown that elastase degrades the basement membrane in order to permit PMN pene-
tration. 
2.2.2 Chemoattractants 
PMN are motile and diverse chemoattractants may recruit them to sites of inflam-
mation. These chemotactic factors include arachidonic acid derivatives such as 
leukotriene B« (LTB*), complement system components such as C5", Cs des arg, 
cytokines such as interleukin 1 (IL 1), PAF and substances derived from micro-
organisms.15-1'7 Arachidonic acid (AA) is a precursor of several biologically active 
compounds. From arachidonic acid three major classes of metabolites are produced; 
the prostaglandins formed via the cyclo-oxygenase pathway, the hydroxyeicosa-
tetraenoic acids (HETE) and leukotrienes via the lipoxygenase pathway. 
2.2.3 The PMN and chemoattractants in psoriasis 
Several data suggest a role for PMN in the pathogenesis of psoriasis. The charac-
teristic finding in the psoriatic lesion is the formation of PMN microabscesses in 
the stratum corneum with penetration of inflammatory infiltrates into the epidermis 
through the elongated papulae.6 According to some authors PMN infiltration is one 
of the earliest histological changes in the so-called pre-pinpoint papules.18 In the 
Koebiier phenomenon induced by tape-stripping similar features are found.10 Other 
authors20, however, report macrophage infiltration as the initial change in devel-
oping psoriatic lesions, the so-called pinpoint papules. The transition from psoriasis 
vulgaris to pustular psoriasis, with massive epidermal infiltration by PMN in the 
latter, also indicates a significant role of the PMN in the pathogenesis of psoriasis. 
However, in lesions of chronic stable plaque psoriasis the frequency of PMN is 
much less.21 In this respect it is of interest that a substantial inhibitmg activity 
has been found against the enzyme elastase. It has been hypothesized that the 
induction of this inhibitor might be responsible for the "off-switch" of PMN in-
vasion in psoriasis.22 
The release of arachidonic acid and its metabolites may be a central event in the 
pathogenesis of psoriasis. In support of this are the increased activity of the regu-
lating enzyme phosphohpase Aa2 3 and the increased amounts of arachidonic acid, 
LTB4, and 12-HETE demonstrated in the psoriatic lesion.2* Elevation of LTB* in the 
lesion of psoriatics may be due to either the PMN infiltrates or increased synthesis 
by the keratinocytes or both.25-2"7 From a clinical point of view the relevance of 
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these metabolites in the pathogenesis of psoriasis has been substantiated. Thus, the 
cyclo-oxygenase inhibitor indomethacm orally or topically applied, results in an 
exacerbation of psoriasis28"20; the 5-lipoxygenase inhibitor, benoxaprofen markedly 
improves psoriasis30"32; eicosapentanoic acid, an indirect LTB^-antagonist improves 
psoriasis.33 
3 AIM OF THE THESIS 
This thesis attempts to elucidate the transepidermal migration of PMN in psoriasis 
and the relationship of the therapies to this movement. In particular the following 
questions are considered: 
1. What are the dynamics of intra-epidermal PMN accumulation following standard-
ized injury in the clinically uninvolved skin of psoriatics? (chapter II) 
2. Do antipsoriatic therapies interfere with the transepidermal migration of PMN 
(chapter IH-VI) and how specific is this interference? (chapter VII) 
3. Is the elastase inhibitor (chapter X) specific for psoriasis and is there a rela-
tionship between inflammation and the elastase inhibiting activity? (chapter IX) 
4. What is the order of events between epidermal hyperproliferation and PMN accu-
mulation in the margin of the psoriatic lesion? (chapter XIII) 
4. GENERAL METHODOLOGY 
4.1 LTB* model 
Topical apphcation of low doses of LTB« (10-500 ng) on normal and uninvolved 
psoriatic skin results in intra-epidermal microabscesses consisting of PMN34-30 (Fig. 
5) followed by mononuclear cell infiltration, vasodilatation and increased epidermal 
proliferation.37 With this in vivo experimental model an intra-epidermal accumulation 
of PMN is obtained with reproducible dynamics34 and dose response relationship.32 
4.2 Stripping of the skin with sellotape 
This is a standard model for experimental studies in psoriasis: repeated applications 
of sellotape result in hyperplasia, an increased number of mitoses, parakeratosis, a 
dermal infiltration with predominantly PMN and intra-epidermal PMN accumulations. 
There is a close histological similarity between the minute papules that develop 6-
96 hours after stripping and the spontaneous pre-pinpoint papules, an initial stage 
in the development of the psoriatic lesion.38 This in vivo model covers the whole 
process of release of chemotactic factors (AA metabolites,39 complement-derived 
anaphylatoxins, non-complement derived chemotactic factors e.g. produced from 
fibrine by plasmin40) and the resulting PMN accumulation in the skin. 
16 
Fig. 5. Microabscesses induced by topical application of 100 ng LTB* are stained 
with anti-elastase peroxidase conjugate in frozen sections of normal skin. 
4.3 The elastase assay 
The fluorometric assay, using elastase as a marker enzyme for quantification of 
PMN developed by Lammers et al4 1 is specific and sensitive. PMN elastase is not 
present in any other type of human cell and as few as 5 PMN can be traced. 
Monocytes contain a small amount of an elastase-like enzyme; its properties how-
ever, are different from the PMN type elastase. This method further provides the 
possibility to assess PMN accumulation in a whole biopsy in one single measurement. 
With conventional histological methods, serial sectioning and investigation of many 
sections would be required to estimate the intra-epidermal penetration of PMN, 
especially as PMN occur in limited amounts or in "hot spots". 
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SUMMARY 
The intra-epidennal accumulation of polymorphonuclear leukocytes (PMN) following 
sellotape stripping of psoriatic non-lesional skin and normal skin of healthy in-
dividuals has been quantified with the elastase assay. Far more PMN accumulated 
in the skin in unstable psoriasis than in stable psoriasis. No significant difference 
was found, however, in PMN accumulation between the psoriatics as a whole, and 
the controls. PMN accumulation was followed by the induction of an elastase 
inhibitor in psoriatic patients and controls. No significant differences could be 
found in inhibitory activity between controls and psoriatics. Our results suggest 
that the degree of PMN accumulation following surface trauma is essentially normal 
in stable chronic plaque psoriasis, but increases in unstable phases of the disease. 
INTRODUCTION 
In psoriasis the presence of large numbers of polymorphonuclear leukocytes (PMN) 
within the diseased epidermis is well known and has been emphasized repeatedly.1 
Histologically these cells accumulate at the boundary between the living cells and 
the stratum corneum, where they form so-called Munro-abscesses. 
The "sellotape strip method"2 produces a controlled injury to the human epidermis 
and has been used frequently in studies on epidermal growth control in psoriasis.3·* 
Jablonska and co-workers5 showed that 90% of specimens from patients with un-
stable psoriasis had PMN exocytosis during the first 3 days after stripping. In 
their controls, 70% of specimens were positive for PMN exocytosis during the first 
20 
day, decreasing to 22% by the third day after stripping. Heng et al.e with the use 
of Ught and electronmicroscopy found no PMN in the first 24 hours after stripping. 
A variable degree of PMN exocytosis was found 7 days after sellotape stripping in 
some of their patients with psoriasis but in none of the normal controls. In these 
important studies evaluation of PMN exocytosis was non-quantitative. The rather 
limited degree of PMN exocytosis following stripping necessitates the use of a 
quantitative and sensitive method for the detection of PMN. 
Recently an ultrasensitive fluorometric method for the quantification of PMN in 
cutaneous infiltrates has been developed, using PMN elastase as a marker enzyme.7 
With this method we have quantified the intra-epidermal accumulation of PMN 
following sellotape stripping of the clinically uninvolved skin of psoriatic patients 
and normal skin of healthy individuals. 
MATERIALS AND METHODS 
Subjects 
Twelve patients with chronic plaque psoriasis participated in this study (Table 1). 
Prior to the investigation disease activity was determined, based on their case 
histories and physical examinations. Criteria for the subgroups were denned as 
follows: 
1. Stable psoriasis: large plaques which occur in typical locations, without periph-
eral spreading or the appearance of new lesions during the last month. 
2. Unstable psoriasis: large plaques, which expand on the periphery during the 
last month and/or small papules or pinpoint lesions surrounding the plaques. 
Table 1. Patients details. Values (colums 4-6) are means ± SD. 
Group 
(subgroup) • 
Controls 
Psoriasis 
vulgaris 
Stable 
Unstable 
no 
12 
12 
7 
5 
M/F 
7/5 
5/7 
4/3 
1/4 
Age 
(years) 
35 ± 10 
39 ± 13 
37 ± 7 
43 ± 18 
Duration of pso-
riasis in years 
25 ± 15 
19 ± 17 
34 ± 15 
Skin involve-
ment (%) 
15 ± 26 
3 ± 2 
31 ± 36 
21 
All patients were members of the Dutch Psoriasis Association and were individuals 
who for ideological reasons had refused treatment for at least a year. At the time 
of the investigation 2 patients were covered with lesions on more than 50% of the 
body surface, yet continued to refuse therapy other than bland emolhents. The 
reason for selecting untreated patients for the experiments was to avoid inhibition 
of PMN accumulation.8·9 For ethical reasons patients with a history of Koebner 
response were excluded. The control group consisted of 12 (approximately age-
matched) healthy individuals. Patients and controls were investigated in pairs to 
exclude possible bias resulting from changing environmental conditions. Medical 
Ethics Committee approval was obtained for this study. 
Experimental procedures 
Blood was obtained by venepuncture of healthy volunteers, and polymorphonuclear 
leukocytes were isolated by standard procedures.1 0 The washed cells ( > 90% neutro­
phils) were lysed by sonification in cetrimide buffer (0.3% cetrimide, 0.1M Tris.lM 
NaCljpH 8.5) at a concentration of 5 χ IO6 cells/ml. All dilutions were made in 
the same buffer. 
Skin on the upper back was stripped by successive applications of sellotape.4 In 
the patients test sites were at least 20 cm from any lesion. Removal of the stratum 
corneum was considered to be complete when the whole area appeared to be glisten­
ing (30-40 applications); no difference was observed between patients and controls. 
Biopsies were taken from the centre of the stripped test sites at 2, 4, 8, 16, 24, 
48, 72 and 168 hours after stripping of the clinically uninvolved psoriatic skin or 
normal skin of healthy individuals. No anaesthetic agent was employed. All speci­
mens were cut freehand using a razorblade in conjunction with a metal guard. 1 1 
The biopsies (average fresh weight 2-3 mg, approximately 3 mm diameter and 
thickness about 0.2 mm) were processed for elastase measurement. 
Biopsies and analytical procedures were, except for some minor modifications 
processed, as described previously."7 In brief, the biopsies were rinsed thoroughly 
in phosphate buffered saline, homogenized in cetrimide buffer and centrifuged. 
Elastase activity of the supernatant was determined by measurement of the fluor­
escence of 7-ainino-4-methylcoumarin released from the substrate MeOSuc-AIa-
Ala-Pro-Val-N-methylcoumarin; endogenous inhibition was corrected by the inclusion 
of an internal standard of elastase (equivalent to 500 PMN). The following incuba­
tion mixtures were set up in dupHcate: 
(a) 20 μΐ sample (b) 20 μΐ elastase standard 
20 μΐ buffer 20 μΐ buffer 
20 μΐ substrate 20 μΐ substrate 
(c) 20 μΐ sample(d) 40 μΐ buffer 
20 μΐ elastase standard 20 μΐ substrate 
20 μΐ substrate 
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After incubation for 1 h, the reaction was stopped by the addition of 1 ml car­
bonate buffer (0.1M, pH 10.5) and fluorescence measured (375 nm excitation, 440 nm 
emission). Enzyme activity and inhibition was calculated as follows: 
Elastase activity (corrected) = (a-d) χ —^—;^  
Percentage endogenous inhibition = 1 ^-^r—^ χ 100% 
The density of infiltrating PMN per 10 (ig skin was calculated using the value of 
0.66 pmol 7-amino-4-methylcoumarm released per hour per PMN. 
Statistical evaluation was performed with the Student's t-test, two-tailed hypothesis. 
RESULTS 
Clinical assessment 
There was no difference between the psoriatic and the control group. In all cases 
an immediate erythema was observed after stripping which faded slowly during the 
subsequent 7 days. After 1-2 days the stripped area was covered with a shiny 
translucent crust, which flaked away during the latter half of the experimental 
period, to leave a slightly scaly surface. By day 14 the skin seemed entirely normal 
except for a variable degree of hyperpigmentation. All test sites of both controls 
and psoriatics healed without complications. Neither overt Koebner reaction, nor 
(pre)pinpoint papules were seen in response to stripping up to one month after 
the end of the experiments. 
Blood PMN 
The mean elastase activity of 6 separate preparations of healthy volunteers was 
0.66 ± 0.072" (SEM) pmol 7-amino-4- methylcoumarin released per hour per PMN. 
Quantification of PMN in cutaneous infiltrates 
The time course of the response for PMN accumulation in the skin following 
sellotape stripping is shown in Fig. 1. As early as 2 h after stripping there was 
an accumulation of PMN. A broad peak was seen with a maximum at about 8 h 
after stripping. In some cases PMN were demonstrated in patients and controls up 
to one week (168 h) following injury. 
Differences in PMN accumulation were not statistically significant, when the pso­
riatic group as a whole were compared with the controls. However, the response 
of patients with unstable psoriasis was strikingly different from that of patients 
with stable psoriasis (Fig. lb), as the PMN infiltration in the former group peaked 
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Fig. J. Time-course of PMN accumulation in (a) healthy controls (open circles, 
η = 12) versus all psoriatic patients (solid circles, η = 12) and (b) patients with unstable 
psoriasis (open squares, η = 5) versus patients with stable psoriasis (solid squares, 
η = 7). Values are means ± SEM. 
at about seven times the level observed in the latter. To provide a measure for 
the PMN accumulation following stripping the area enclosed by the curve relating 
time (0-24 h) and number of PMN was calculated in all patients. There was a 
statistically significant difference between unstable psoriatics compared to stable 
psoriatics (Student's t-test ρ < 0.005). 
Inhibitory activity for elastase in skin extracts 
The time courses of inhibition of a standard elastase preparation of the skin 
extracts following stripping are illustrated in Fig. 2. Between 2 and 8 h after 
stripping the mean inhibitory activity in normal and psoriatic skin was 8.1 ± 3.1% 
(SEM; η = 68 specimens). With remarkable consistency, inhibition increased 8 h 
after stripping, and reached a maximum inhibition at 48 h of 64.4 ± 7.5% (mean ± 
SEM; η = 24 specimens) and slowly returned to normal values at 168 h. No sig­
nificant differences were found in inhibitory activity between controls and psoriatics 
as a whole, or between unstable and stable psoriatic patients. 
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Fig. 2. ïïme-course for the appearance of endogenous elastase inhibitor in the 
skin extracts, (a) Healthy controls versus all patients and (b) unstable versus stable 
psoriasis. Symbols and numbers as in Fig. 1. 
DISCUSSION 
The present observations on the clinical behaviour of the stripped skin are in 
line with our earlier experiences* In contrast to the suggestion of Reinertson12, 
we did not find a positive Koebner reaction in patients with unstable psoriasis. 
It might be of relevance, however, that our patients were selected on a history of 
a negative Koebner response. 
The ëlastase assay is a simple, reproducible and sensitive method for the quan-
tification of PMN in skin infiltrates. It enables one to detect as few as five PMN 
per assay7, which would certainly be missed with histological methods. A possible 
disadvantage of the assay is that PMN accumulation can only be assessed reliably 
during the first 24 h following stripping. During this period the effects of the 
elastase inhibitor present in skin extracts may be accurately compensated for by 
the use of an internal standard. Beyond this period the inhibitor increased to such 
an extent that the correction factor became unacceptably large, and the quantifica-
tion of PMN inaccurate. Despite this, PMN were detected in some subjects for at 
least 1 week after stripping. 
Chowaniec et al.13 have proposed that the order of events in the pathogenesis of 
the psoriatic lesion is PMN accumulation followed by epidermal hyperproliferation. 
Our observations in the stripping model are compatible with this sequence. The 
elastase assay showed PMN accumulation in the normal-looking skin of all individ-
uals as soon as 2 h after sellotape stripping, followed by a rapid increase in PMN 
accumulation. The parameters for cell cycle kinetics remained within the normal 
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range for the first 24 h and increased abruptly after about 48 h.* A similar order 
of events is provided by the changes induced by epicutaneous application of leuko-
triene B4. In this situation epidermal hyperproliferation is also preceded by intra-
epidermal accumulation of ΡΜΝΛ4 
After the appearance of PMN in the first hours following sellotape stripping an 
abrupt and dramatic induction of an elastase inhibitor was demonstrated in all 
subjects. Its possible role is unknown, but it may be part of a regulating mechanism 
for PMN invasion. Elastase is believed to facilitate the penetration of PMN into 
tissues;15 the inhibitor may prevent PMN elastase from degrading the basement 
membrane of the skin and thus prevent the penetration of PMN into tissues. As 
such the inhibitor could well be part of an on-off switch mechanism, that controls 
and regulates PMN invasion. 
In this study the differences in PMN accumulation between psoriatics as a whole 
and controls were not statistically significant. Our findings agree with the "in 
vitro experiments" reported by Cunningham and co-workers; no significant difference 
in either the random migration or the chemotactic response of psoriatic circulatory 
PMN to LTB* was found when compared to the response of PMN from healthy 
controls.1 0 At first glance our present findings are surprising in the light of the 
decreased intra-epidermal accumulation of PMN following topical application of 
leukotriene В* to the clinically uninvolved skin of psoriatic patients. 1 7 · 1 8 The 
decreased responsiveness could be interpreted as tolerance to the increased produc­
tion of leukotriene B* in the non-lesional skin of psoriatics.1* The present inves­
tigation offers a synthesis between the production of chemotactic substances and 
the response of PMN in vivo. The integrated function of both phenomena appears 
to be normal, although the individual phenomena are abnormal. 
Although the ranges of PMN accumulations following surface trauma are similar 
in psoriatics and normal controls, there is a highly significant difference within 
the psoriatic group. Patients with unstable psoriasis showed 750% more PMN ac­
cumulation than patients with stable psoriasis, whereas no significant correlation 
was shown with the extent of skin involvement. In blood PMN of psoriatic patients 
neutral proteinases, including elastase have been measured by Glinski et al. 2 0 They 
showed a statistically significant increase in unstable psoriasis, which suggests 
that the circulatory PMN contributes to some extent in the disease activity-related 
difference observed in this study. 
In conclusion, the intra-epidermal accumulation of PMN might represent a link 
between triggering factors and the aggravation of skin lesions.21 
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Chapter ΠΙ 
Topical application of clobetasol-17-propionate inhibits 
the intra-epidermal accumulation of polymorphonuclear 
leukocytes 
A. Chang and P.C.M. van de Kerkhof 
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The Netherlands 
Acta Dermato-Venereologica (Stockh) 1988; 68: 57-60 
ABSTRACT 
The in vivo effect of topical clobetasol-17-propionate (CP) on the leukotriene B.*-
and trauma-induced intra-epidermal accumulation of polymorphonuclear leukocytes 
(PMN) was investigated in normal volunteers. PMN accumulation was assessed using 
elastase, a specific and sensitive marker for these cells. A profound inhibition of 
PMN accumulation was shown in the first 2 days of treatment with CP, an effect 
that faded away after a treatment of 2 weeks. Key words: Corticosteroids; polymor­
phonuclear leukocyte; elastase; leukotriene B*; skin trauma. (Received July 16, 1987.) 
A. Chang, Department of Dermatology, University of Nijmegen, Philips van Leyden-
laan 25, 6525 EX Nijmegen, The Netherlands. 
INTRODUCTION 
Clobetasol-17-propionate (CP) is a potent corticosteroid preparation with an ex­
ceptional clearing capacity in psoriasis.1 A wide range of working mechanisms have 
been reported including an antimitotic effect, normalization of keratinization pattern 
and immunomodulations.2 
The intra-epidermal penetration of polymorphonuclear leukocytes (PMN) is an early 
event in the pathogenesis of the psoriatic lesion and their arrangement as 
spongiform pustules is characteristic of the disease.3 
In the present study normal skin was treated with CP creme and its vehicle only 
(placebo), and following a chemotactic signal, the intra-epidermal accumulation of 
PMN was measured. The enzyme elastase which allows accurate quantification of 
skin PMN was used as marker.4 The chemotactic signals were: 
(i) topical application of leukotriene B* (LTB*), which produces microabscesses 
of PMN in the epidermis.5·0 
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(ii) standardized injury (sellotape stripping), which brings about an endogenous 
release of chemoattractants and causes intra-epidermal accumulation of small 
amounts of PMN.7 
MATERIALS AND METHODS 
Subjects and treatments 
Eight subjects without signs or previous history of skin diseases participated in 
this study. The group consisted of 5 females and 3 males, aged between 22 and 31 
years. Prior consent of the Medical Ethics Committee was obtained for these ex­
periments. 
In a double blind approach, 0.05% CP creme (Dermovate cremeR, Glaxo) and the 
placebo (skin base cremeR, Glaxo) were applied thinly and evenly without occlusion 
on two different demarcated test areas (10 χ 10 cm) localized on the left or right 
upper arm. The crèmes were applied twice daily for a period of 2 weeks, except 
on the day of LTB* application and sellotape stripping. 
LTB* application and sellotape stripping 
LTIU was purchased from Paesel GmbH Frankfurt, Germany. Twelve hours after 
the second application of CP and placebo creme the test areas were cleansed with 
70% ethanol. Aliquots of 20 ng LTB* in ethanol were then applied onto 5.5 mm 
circular patches within the CP and placebo test areas, as well as on an untreated 
skin region of the upper arm. The ethanol was evaporated with a stream of nitro-
gen. The three LTB* application sites were marked with eosin and covered with 
impermeable dressings (Silverpatch, van der Bend, Brielle, The Netherlands). 
Biopsies of LTS.« treated sites were taken freehand using a razor-blade in con-
junction with a metal guard 24 h following the application (time of maximum 
accumulation of PMN). Treatment with CP creme and placebo creme was continued 
for 14 days. Twelve hours after the last application of these crèmes, the proce-
dure of LTBi application followed by biopsy was repeated for the CP- and place-
bo-treated areas. 
Twelve hours after the second application of the crèmes, three circular regions 
(15 mm diameter) were stripped by repeated application of sellotape. Two of the 
regions were within the CP- and placebo-treated areas; the third was an untreated 
area on the upper arm. Removal of the stratum corneum was considered to be 
complete when the whole area appeared to be glistening (30-40 applications). 
Razor-blade biopsies in combmation with a metal guard (hole 5.5 mm diameter) 
were taken from the centre of the stripped sites 8 h later (time of maximum 
accumulation of PMN). After 14 days of treatment (12 h after the last application 
of the crèmes) this procedure was repeated for the CP- and placebo-treated areas. 
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Analytical procedures 
Biopsies (average fresh weight 3 mg) were processed for elastase measurement as 
described previously.4 In brief, biopsies were homogenized in cetrimide buffer after 
thorough washing in phosphate buffered saline. Elastase activity was measured in 
duplicate 20 μΐ aliquots of the supernatants from the fluorescence of 7-amino-4-
methylcoumarin released from the substrate MeOSuc-Ala-Ala-Pro-Val-N-methylcou-
marin. The density of infiltrating PMN per 10 μg skin was calculated after correc­
tion for elastase inhibitors.4 
Statistical analysis 
The Wilcoxon ranking test for paired data was used in the statistical analysis. 
Level of significance, 0.05. 
RESULTS 
During the first days of treatment no blanching occurred. After about one week 
the CP-treated areas of all subjects showed mild erythema with slight scaling, 
whereas the placebo-treated area showed no abnormalities. In 2 subjects the picture 
was complicated by folliculitis within the CP-treated test areas. 
PMN accumulations 24 h following LTB« applications are given in Fig. 1. After two 
applications of CP, a reduced responsiveness occurred vis-à-vis the placebo-treated 
area or untreated area (both ρ < 0.025). After 14 days of treatment with CP, no 
significant differences could be demonstrated between the CP-treated, placebo-
treated and untreated areas. 
PMN accumulations 8 h following sellotape stripping are given in Fig. 2. After two 
applications of CP a markedly reduced responsiveness occurred, vis-à-vis the pla-
cebo-treated and untreated areas (p = 0.01 and ρ < 0.01, respectively). After 14 
days of treatment with CP, no significant difference could be shown vs. placebo-
treated or untreated areas. 
DISCUSSION 
After CP treatment for one day, LTB4-induced PMN accumulations were reduced to 
30% of the responses observed following treatment with the placebo. Trauma-induced 
PMN accumulations were inhibited even more profoundly; in the CP-treated areas 
they averaged only 12% of the responses measured after treatment with the vehicle. 
After a treatment period of 14 days the situation was less certain; PMN accumulation 
could not be shown to be significantly affected by CP treatment. However, all 
subjects developed a slight dermatitis and a folliculitis was seen in 2 of them, which 
could account for the wide range of PMN accumulations. Such clinical effects have 
been observed occasionally in patients treated with CP creme twice daily.1 
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Fig. 1. Intra-epidermal accumulation of 
polymorphonuclear leukocytes 24 h after 
topical application of 20 ng leukotriene 
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Fig. 2. Intra-epidermat accumulation of 
polymorphonuclear leukocytes 8 h fol­
lowing sellotape stripping of the skin 
of 8 normal volunteers. The shaded 
area represents the normal range (mean 
± SEM) of untreated skin following 
sellotape stripping. O Skin treated with 
placebo creme (mean ± SEM); · Skin 
treated with clobetasol-17 propionate 
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The present in vivo study, with the dermis and epidermis acting as a natural dif­
fusion chamber, demonstrates that the LTB^-induced Chemotaxis is reduced fol­
lowing CP treatment. A more precise localization of the action site of CP would 
require in vitro studies. The PMN itself could well be the target cell for cortico­
steroids. Indeed it has been shown that incubation of PMN derived from peripheral 
blood with corticosteroids reduces the chemotactic activity of these cells.0 An 
alternative explanation for the action of CP might be an interference with the 
interaction between PMN and endothelial cells. Several authors have reported the 
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aggregation of PMN and the adhesion of these cells to the endothelium induced by 
mediators of inflammation including LTB4. 9 · 1 0 
It has been shown that corticosteroids inhibit the adhesion of PMN to endothelial 
cells in vitro1 1, which might reduce PMN passage into the skin. 
Following trauma, mediators of inflammation are released, including arachidonic 
acid metabolites. Corticosteroids have been reported to inhibit arachidonic acid 
release by inducing the phospholipase A2 inhibitor lipomodulin.12 Thus, in trauma-
induced PMN accumulation a synergistic modulation by CP is feasible: inhibition of 
endogenous release of mediators of inflammation and inhibition of the effect of 
the mediator LTB* on PMN penetration. 
In previous studies we have shown that systemic treatment with etretmate and 
methotrexate in dosages used for the treatment of psoriasis inhibits the LTB*-
induced intra-epidermal accumulation of P M N . 0 · 1 3 · 1 4 It is of interest that these 
systemic treatments and topical therapy with CP, although strikingly different in 
the spectrum of diseases that are responsive to each of these, share two key 
features: a potent antipsoriatic working and inhibition of intra-epidermal accumula­
tion of PMN. 
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Chapter IV 
Dithranol modulates the leukotriene EU-induced intra-
epidermal accumulation of polymorphonuclear leukocytes 
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ABSTRACT 
Dithranol, with and without the addition of salicylic acid, was applied daily on 
normal skin according to a short contact protocol as used in the treatment of 
psoriasis. Scllotape stripping and epicutaneous application of leukotriene Вл (LTB*) 
were carried out within these pre-treated areas. The challenged skin was sub­
sequently biopsied and the intra-epidermal accumulation of polymorphonuclear 
leukocytes (PMN) was quantified using the marker enzyme elastase. 
Dithranol pretreatment yielded a significant reduction of the LTBA-induced ac­
cumulation of PMN, whereas the tape stripping-induced accumulation of PMN was 
not affected by dithranol pretreatment. The addition of salicylic acid did not 
significantly enhance the effect of dithranol. 
INTRODUCTION 
For many years dithranol has been a classical therapy for psoriasis.1 For reason 
of its great clinical efñcacy and safety new application formulations and therapy 
schedules have been developed during the last decade, including dithranol creams 
and short-contact schedules.2 
At a molecular level dithranol works via free radical intermediates.3 However, it 
is not known which compartments are the targets for the antipsoriatic effect. A 
direct effect of dithranol on epidermal cell cycle kinetics has been established.4·5 
On the other hand it has been shown that dithranol affects the blood derived 
polymorphonuclear leukocytes (PMN) directly.0·"7 Histological studies of psoriatic 
lesions during treatment with dithranol indicated that the epidermal acanthosis 
and parakeratosis normalizes well before8 or simultaneously with the disappearance 
of the inflammatory changes, including the intra-epidermal accumulation of PMN.9 
The aim of the present investigation is to study the effect of dithranol on the 
migration of PMN into the epidermis 'in vivo' after a standardized chemotactic 
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signal. Skin of normal controls was treated with dithranol creams, according to a 
standard schedule for short contact therapy: one area with and one area without 
the addition of salicylic acid; a third area was treated with the cream base only. 
Sellotape stripping and epicutaneous application of leukotriene Вл (LTBa) was 
carried out on each of the 3 test areas . 1 0 · 1 1 Following these stimuli, the intra-
epidermal accumulation of PMN was quantified in microbiopsies, using elastase as 
a marker enzyme.1 2 
MATERIALS AND METHODS 
A group of 11 healthy volunteers, without signs or history of skin diseases, par­
ticipated in the investigation. The subjects (6 males and 5 females) were between 
22 and 35 years old. Prior consent of the Medical Ethics Committee was obtained 
for this experiment. In each of the volunteers 3 areas on the upper arms (10 χ 5 
cm
2) were treated on 8 consecutive days with: 
(i) dithranol (0.5%; 1.0%; 2% or 3%) each containing salicylic acid 2% in a cream 
base (Psoralon11 MT, Hermal Kurt Herrmann, Reinbek, Germany); 
(ii) dithranol (0.5%; 1.0%; 2% or 3%) in the same cream base without salicylic acid 
(Hermal-Chemie); 
(iii) the vehicle only, without dithranol or salicylic acid (Hermal-Chemie). 
The creams were applied thinly and evenly on the test areas. After an application 
period of 20 minutes the creams were removed by washing with an acid soap. The 
concentration of dithranol was increased on alternate days, if no or only slight 
erythema or subjective discomfort, or both, was experienced. On every day the 
subjective sensations, erythema and discoloration were recorded. 
Approximately 12 h after the last treatment LTB* application and sellotape stripping 
were carried out on each of the 3 test areas . 1 0 · 1 1 LTB* was obtained from Paesel 
GmbH (Frankfurt, Germany). A 10 μΐ droplet containing 10 ng LTB* in ethanol 
was applied through a glass cylinder (5.5 mm diameter) and the ethanol was evap­
orated under a stream of nitrogen. The sites of LTB* application were marked 
with eosin and covered with impermeable dressings ('silver patch', van der Bend, 
Brielle, The Netherlands) until the biopsies were taken (24 h). Sellotape strippmg 
was carried out by the repeated application of 'Tesafilm' pressure sensitive tape 
(Beiersdorf BV, Aalsmeer, The Netherlands). Following 30-40 applications of tape 
the whole area appeared glistening and microscopic examination of the tape surface 
showed that no more cells were removed after this point. From the LTB^-treated 
and tape-stripped sites microbiopsies (approximately 3 mm diameter and 0.2 mm 
thick) were taken freehanded using a razor blade in conjunction with a metal 
guard, 24 h and 8 h after those procedures respectively. In addition, biopsies were 
taken from the treated areas without previous LTB* application or sellotape strip­
ping. 
Biopsies were rinsed thoroughly in phosphate buffered saline, dried between filter 
paper and weighed (2-3 mg). After homogenization at 2 mg/ml in buffer (0.3% 
cetrimide, 0.1M Tris, IM NaCl, pH 8.5) using an all-glass Potter-type grinder, 
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elastase activity was measured in the supernatant fraction after centrifugation 
(3000 g for 10 min), as described by Lammers et a l . 1 2 In brief, a 250 μΜ solution 
of the fluorogenic substrate MeOSuc-Ala-Ala-Pro-Val-N-methyl-coumarin in buffer 
containing cetrimide was prepared. A 20 μΐ aliquot of this solution was incubated 
with a 20 μΐ aliquot of the skin supernatant for 1 h at ЗТС. The reaction was 
terminated by cooling in ice and diluting to 1 ml with carbonate buffer (0.1M, pH 
10.5). Fluorescence was measured at excitation 375 nm and emission 440 nm, using 
a Perkin-Elmer LS 5 spectrofluorometer. Normal skin (healthy volunteers) contains 
no elastase activity, but inhibits the PMN enzyme (mean inhibition 12%). For this 
reason elastase activity was corrected by the inclusion of an internal standard of 
elastase (equivalent to 500 PMN) as described in Chang et al. 1 0 The number of 
PMN per 10 μg skin was quantified using the value of 0.66 pmol of 4-methyl-7-
aminocoumarin released per hour per PMN. In 'in vitro' experiments dithranol 
showed no inhibition of PMN elastase when 500 mg creams (15 mg dithranol with 
or without 10 mg salicylic acid) were incubated with 5 χ 104 PMN in 1 ml cetrimide 
buffer for 1 h at 20oC. Thus, under these conditions dithranol does not inhibit 
elastase. We have further shown that dithranol does not contribute directly to the 
measured fluorescence under the conditions described. 
Statistical evaluation was carried out with the Wilcoxon ranking test for paired 
data. 
RESULTS 
In all subjects the concentrations of dithranol could be increased on alternate 
days. At the end of the treatment period, all volunteers were treated with dithranol 
3.0%. Erythema, irritation or discoloration occurred in 9 out of the 11 subjects. In 
4 individuals these side effects were more pronounced in the areas treated with 
dithranol cream containing salicylic acid. However, in 1 subject the area treated 
with dithranol without salicylic acid showed a more marked erythema. Details 
regarding the clinical responses are shown in Table 1. 
Table 1. Number of subjects responding with side effects to 20 min applications 
of dithranol creams. 
dithranol 
0.5 
1.0 
2.0 
3.0 
(%) erythema 
0 
2 
7 
8 
(n) irritation 
0 
1 
3 
3 
(n) discoloration (n) 
0 
0 
2 
7 
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Fig. 1 shows the accumulations of PMN, induced by sellotape stripping or LTB*, 
within the 3 test areas: treated with vehicle only, treated with dithranol, treated 
with dithranol and salicylic acid. Following sellotape stripping, the PMN accumula-
tions were similar in all 3 test areas. In contrast, dithranol had a marked effect 
on the PMN accumulations induced by LTIU. The LTIU-induced PMN accumulations 
were dramatically decreased in the skin area treated with dithranol and salicylic 
acid, compared to the accumulations in the test areas treated with the cream base 
only (p < 0.005). In the areas treated with dithranol cream, without salicylic acid, 
the LTB^-induced PMN accumulations were significantly decreased compared to the 
accumulations in the test areas treated with the cream base only (p < 0.025). 
Although the effect of dithranol tended to be greater when salicylic acid was 
added, a statistically significant difference was not reached. In the biopsies taken 
from treated areas without LTB* application or sellotape stripping no PMN ac-
cumulation occurred. 
PMN/10>4 skin . 
stripping LTBt 
3 0 0 -
200 
100 
Fig. 1. PMN accumulations induced by sellotape stripping and application of 10 ng 
LTB* in 3 treated skin areas of 11 normal volunteers. Bars represent mean 
± SEM. 
In all biopsies the endogenous inhibition of a standard preparation of PMN elastase 
was assessed. The degree of inhibition in the biopsies of all treatment groups, 
stimulated with LTB,» or by sellotape stripping, was below 15% and did not differ 
significantly from the inhibition of untreated and unchallenged normal skin. 
f · ' " ! Vehicle 
I I Dittranol-salicytic 
_ acid 
EZä DithranoLsaiicylic 
acid 
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DISCUSSION 
The present study clearly shows that dithranol inhibits the transepidermal migration 
of PMN 'in vivo'. Several explanations for this observation are possible. Firstly, a 
direct inhibition of PMN Chemotaxis has been described.6·7 However, in the present 
study a time lag of 12 hours exists between the last application of dithranol and 
the challenge with LTB*. Although we cannot rule out a direct interference of 
dithranol with PMN Chemotaxis with certainty, the time lag makes this unlikely. 
An alternative possibility might be the effect of dithranol on the endothelial cells. 
The aggregation of PMN and the adhesion of these cells to the capillary wall are 
mediated by LTB*.13 ·14 The chronic inflammatory effect of the increasing con-
centration of dithranol might decrease the capacity of the endothelial cells to 
interact with the PMN after LTB.* challenge. 
A third explanation is the induction of inflammatory eicosanoids with inhibiting 
properties toward the LTBa-induced Chemotaxis such as prostaglandin Ez (PGEz) 
and 15-hydroxyeicosatetraenoic acid.15,10 It has been reported that a single applica-
tion of 3% dithranol to the uninvolved skin of psoriatics induces raised PGEz levels 
in suction bullae exudate.17 
The addition of salicylic acid in concentrations up to 2% has a preservative effect 
on dithranol if the base is a zinc paste; however, in other vehicles the preservative 
effect of salicylic acid has never been proven.1019 Salicylic acid in higher con-
centrations enhanced the penetration of other drugs.20 However, as far as we 
know, such an effect has not been confirmed for lower concentrations of salicylic 
acid. The present investigation shows a tendency for a slightly increased potency 
of the combined formulation compared to the preparation containing dithranol 
only, indicated by the clinical parameters and the PMN accumulation following 
LTB4 challenge. However, this difference is by no means statistically significant. 
Remarkably, dithranol did not change the response to sellotape stripping. An ex-
planation for this discrepancy is provided by the interference of dithranol with 
the metabolism of inflammatory eicosanoids. In the model of sellotape stripping, 
the endogenous generation of mediators of inflammation is an integral part, whereas 
this process is bypassed in the model of LTB^-induced PMN accumulation. Dithranol 
proved to inhibit the formation of LTB.» and 12-hydroxyeicosatetraenoic acid.21 ,22 
However, these studies indicated that the inactivation (a;-oxidation) of LTB* is 
inhibited at substantially lower concentration. Therefore in skin treated with 
dithranol, this interference might result in a relative overflow of inflammatory 
eicosanoids following the physiological generation of these substances by a stimulus 
such as sellotape stripping. The relatively higher levels, resulting from the apphca-
tion of a single dose of 10 ng of LTB«, might be less affected by dithranol-induced 
inhibition of w-oxidation. 
In contrast to the situation following dithranol therapy, treatment of normal skin 
with a potent corticosteroid resulted in a more substantial inhibition of the PMN 
accumulation following sellotape stripping compared to a mild inhibition of the 
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LTB^-induced PMN accumulations.23 This difference was interpreted as a decreased 
formation of inflammatory eicosanoids by the induction of lipocortin, an inhibitor 
of the enzyme phospholipase A*. 
Up to now several therapies for psoriasis have been shown to inhibit the LTB-*-
induced accumulation of PMN: topical corticosteroids, methotrexate and etretina-
t e 23.11.24.25 Therefore, the movement of the PMN through its natural diffusion 
chamber skin seems a relevant target for the treatment of psoriasis. 
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Chapter V 
PUVA and UVB inhibit the intra-epidermal accumulation 
of polymorphonuclear leukocytes 
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SUMMARY 
Healthy volunteers were treated on test areas with UVB irradiation or topical PUVA 
therapy. The trauma-induced and leukotriene B<* (LTB^-mduced intra-epidermal ac­
cumulation of polymorphonuclear leukocytes (PMN) was quantified after these 
treatments, using elastase as a marker enzyme.Both UVB and PUVA treatment 
caused a profound inhibition of trauma- and LTB-*-induced PMN accumulation. This 
observation indicates that the reduction of the transepidermal migration of PMN 
might be part of the mechanism of action of UV therapies in psoriasis. Several 
possibilities are discussed to explain this hypothesis. 
INTRODUCnON 
In psoriasis hyperproliferation and abnormal differentiation of keratinocytes, which 
lead to scaling, are observed. These alterations in the growth and differentiation 
of keratinocytes are not specific to psoriasis, however. The phenomenon charac­
teristic of psoriasis is transepidermal migration of PMN, a process which is thought 
to play a role in the pathogenesis of the disease. 
Ultraviolet В (UVB) and psoralen plus ultraviolet A (PUVA) are standard therapies 
for psoriasis. In both treatments a direct effect on epidermal growth has been 
demonstrated.1·2 However, the beneficial effect of light therapies in disorders 
such as vitiligo, alopecia areata, lichen planus and mycosis fungoides suggests an 
immunomodulatory effect.3 
In the present study, we assessed the effects of UVB phototherapy and topical 
PUVA treatment on the intra-epidermal accumulation of PMN in normal skin fol­
lowing a chemotactic stimulus. The enzyme elastase, which allows accurate quan­
tification of cutaneous PMN, was used as a marker.** The chemotactic stimuli were: 
topical application of leukotriene B* (LTB*), which produces microabscesses of 
PMN in the epidermis5 and standardized injury (sellotape stripping), which brings 
about an endogenous release of chemoattractants and thus causes intra-epidermal 
accumulation of PMN.0 
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METHODS 
Subjects and experimental schedules 
For all experiments the non-sunexposed back skin of 12 healthy Caucasian volun­
teers, seven males and five females, was used. Six volunteers (mean age 28 years, 
range 25-35 years, skin types II and III) participated in the experiment with UVB 
treatment. The other six volunteers (mean age 29 years, range 25-35 years, skin 
types II and III) participated in the experiment with PUVA treatment. 
Experiments lasted 9 days. On days 1, 2, 4 and 5 irradiation with UVB, PUVA or 
UVA was given. On day 8 sellotape stripping0 and LTB* application7 was performed 
on irradiated areas, areas treated with 8-methoxypsoralen (8-MOP) only and on 
control (untreated) areas. On days 8 and 9 shave biopsies were taken from the 
tape-stripped sites and the sites to which LTB* had been applied. In addition, 
biopsies were taken from the irradiated areas and from unexposed areas without 
previous LTB4 application or sellotape stripping. Consent of the Medical Ethics 
Committee was obtained prior to the experiments. 
UVB therapy 
A skin area measuring 10x10 cm was exposed to UVB irradiation, using a Saal-
mann-SUP (selective ultraviolet phototherapy) lamp (Gerhard Saalmann, Herford, 
West Germany). This high pressure mercury vapour lamp emits a spectrum ranging 
from 290-340 nm, with maximal emission between 310 and 320 nm. The UV radiation 
flux was 0.58 mW/cm2, measured at the skin surface with a digital UV meter 
(Waldmann & Co, Schwenningen, West Germany). Treatment was started at 100% of 
the individual minimal erythema dose (MED).8 The mean MED was 51.1 mJ/cm2 
(i.e. 88 s). During consecutive treatments the dosages were increased by 40% if no 
(or only slight) erythema developed. The preceding dose was repeated if erythema 
ensued with discomfort. If a subject developed erythema accompanied by pain, 
irradiation was temporarily discontinued. The mean cumulative dose was 330.6 
mJ/cm2 made up of 4 irradiations in 1 week. Non-irradiated contralateral 10x10 
cm skin areas served as controls. 
PUVA therapy 
In each subject four areas of 10x10 cm were delineated for treatment. One area was 
painted with 5 μΐ/cm2 aliquot of 0.15% 8-MOP emulsion (MeladinineR) (Boehringer 
Ingelheim Haarlem, Holland) and 0.5-1 h later UVA irradiation was given. The 
second and third areas were treated with 8-MOP alone and UVA alone, respectively 
and the fourth area was left untreated. UVA irradiation was given in a Waldmann 
PUVA 6001 cabin (H. Waldmann & Co, Schwenningen, West Germany). The emission 
spectrum of the 40 Philips TL 85W/09 lamps was in the range 320-390nm, with 
maximum emission at 365 nm. Irradiance measurements were monitored using a 
built-in PUVA radiometer. Treatment was at 100% of the individual minimal photo-
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toxic dose" (mean MPD 0.45 J/cm2, i.e. 125 seconds), which was maintained through-
out the treatment without any adverse effects. 
LTB4 application, sellotape stripping and biopsies 
On day 8 (3 days after the last irradiation, 10 ng aliquots of LTB« (Paesel GmbH 
Frankfurt, Germany) were applied through glass cylinders onto 5.5 mm circular 
patches7 in each of the treated and untreated areas. Application sites were marked 
with eosin and covered with impermeable dressings (Silverpatch, van der Bend, 
Brielle, The Netherlands). At the same time, circular regions (15 mm diameter) 
were stripped6 by repeated application of sellotape (30-40 apphcations) in the 
treated and untreated areas. Sellotape stripping was discontinued when the whole 
test site appeared to glisten, and microscopic examination of the sellotape strips 
revealed no horny cells. Biopsies, using a razor blade in conjunction with a metal 
guard, were taken from the centre of the stripped test sites 8 h after stripping 
(time of maximum accumulation of PMN).e On day 9 (24 h after LTB* application) 
razor blade biopsies were taken from the LTB* treated sites (time of maximum 
accumulation of PMN).3 In order to exclude the presence of PMN induced by 
irradiation, additional biopsies were taken from each of the treated and untreated 
areas, without LTBu application or sellotape stripping. 
Analytical procedures 
The biopsies (mean fresh weight 3 mg) were processed for elastase measurements 
as described previously.4 Briefly, biopsies were washed thoroughly in phosphate 
buffered saline, weighed, homogenized in a buffer containing cetrimide and cen-
trifuged. Elastase activity was measured in supernatant fractions using the fluoro-
genie substrate MeOSuc-Ala-Ala-Pro-Val-N-methylcoumarin. Normal skin (healthy 
volunteers) contains no elastase activity, but inhibits the PMN enzyme (mean 
inhibition 12%)."* For this reason elastase activity was corrected for endogenous 
inhibition by the inclusion of an internal standard of elastase (equivalent to 500 
PMN). PMN were quantified using the value of 0.66 pmol of 4-methyl-7-amino-
coumarin released per hour per PMN.6 
Statistical analysis 
The Wilcoxon matched pairs signed rank test was used. 
RESULTS 
On day 2 each of the six subjects who received UVB irradiation developed an 
asymptomatic slight erythema, sharply confined to the treated areas. This was 
succeeded by a barely perceptible tan or slight hyperpigmentation on day 4 or 5, 
which lasted for several weeks. In the PUVA treated subjects a slight to moderate 
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asymptomatic pink erythema, again with well defined borders, was observed on day 
4, which persisted for several days, without increasing redness. On day 8 a variable 
degree of hyperpigmentation was seen, lasting for several weeks. No changes were 
observed in the UVA irradiated, 8-MOP treated or untreated areas. 
PMN accumulation 8 h after stripping and 24 h after LTB-* application is shown in 
Figs 1 and 2. UVB-irradiated stripped sites and UVB-irradiated LTB^-treated sites 
had significantly less PMN accumulation than sites that were only stripped or only 
treated with LTB.* (both ρ < 0.025) (Fig. 1). A similar response was seen following 
PUVA treatment. In the PUVA treated areas, PMN accumulation was again sig­
nificantly inhibited at the stripped sites (p < 0.025) and at the sites of L T B A 
application (p < 0.05), compared with the PMN accumulation at the 8-MOP treated, 
UVA treated and untreated areas (Fig. 2). There was no significant difference 
between these three control sites. In the biopsies taken from treated areas and 
untreated areas without LTB^ application or sellotape stripping no PMN accumulation 
had occurred. 
In all biopsies the endogenous inhibition of a standard preparation of PMN elastase 
was measured. The degree of inhibition in the biopsies of all treatment groups, 
stimulated with LTB» or by sellotape stripping, was below 15% and did not differ 
significantly from the inhibition of untreated and unchallenged normal skin. 
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Fig. 1. Intra-epidermal accumulation of 
PMN 8 h after sellotape stripping and 
24 h after epicutaneous application of 10 
ng LTB* to untreated and UVB irradiated 
skin of six normal volunteers. Bars 
represent means ± SEM. 
Fig. 2. Intra-epidermal accumulation of 
PMN 8 h after sellotape stripping and 
24 h after epicutaneous application of 
10 ng LTB* to PUVA irradiated and 
control skin of six normal volunteers. 
Bars represent means ± SEM. 
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DISCUSSION 
The present study demonstrates that PUVA and UVB phototherapy profoundly 
suppress both the trauma-mduced and the LTB^-induced intra-epidermal accumulation 
of PMN. This inhibition was caused by four exposures of normal skin to either 
UVB or PUVA according to the dosage schedule used in the routine treatment of 
psoriasis in our department. In the subjects participating in the present study, the 
clinical responses were limited to asymptomatic slight to moderate erythema, fol-
lowed by a variable degree of hyperpigmentation. In contrast to PUVA and UVB, 
UVA irradiation did not affect the transepidermal PMN migration, which is in 
accordance with the substantially higher dosages required for a phototoxic effect. 
The transepidermal migration of PMN is an integral function of the circulating 
blood PMN, the generation of mediators of inflammation and the skin itself with 
capillaries, dermis and epidermis including facilitating and inhibiting regulatory 
systems. These different components will be discussed briefly, in order to explain 
the decreased transepidermal migration of PMN by UV therapies found in the 
present study. 
Both PUVA and UVB may affect the circulating blood PMN. Following whole body 
PUVA therapy a temporary decrease in circulating blood PMN,10 and a decrease in 
chemotactic activity of PMN has been reported.11 However, other authors could 
not confirm this.12 Whole body UVB irradiation has been shown to enhance gra-
nulocyte function and increase the number of circulating blood PMN.13 In the 
present study, trauma and LTB* challenge were given at least 3 days after the last 
UV dose. Therefore, the inhibition of the transepidermal migration of PMN at 
the UVB and PUVA treated areas cannot be the result of direct interference by 
UVB or PUVA with the PMN on its way to the epidermis. 
The trauma-induced PMN accumulation includes the generation of mediators of 
inflammation, whereas the LTB^-induced PMN accumulation bypasses this step. In 
the PUVA and UVB treated areas the inhibition of PMN accumulation following 
sellotàpe stripping was of the same order of magnitude as the inhibition of PMN 
accumulation following LTB^ application. If PUVA or UVB inhibit the generation 
of leukoattractants the inhibition of PMN accumulation following sellolape stripping 
should have been greater than that following LTB* application in the treated areas, 
as we observed previously following pretreatment with corticosteroids.14 This earlier 
observation is in accordance with a direct inhibition of the production of inflam-
matory eicosanoids via the induction of lipomodulin15 in addition to interference 
with the response of PMN to LTB*. 
The movement of the PMN through the skin might be enhanced or inhibited at 
several levels. Ultraviolet irradiation causes a release of inflammatory eicosanoids, 
some of which may counteract the LTB^-induced Chemotaxis. Prostaglandin Ez is 
released following UVB, but not following UVA irradiation.10 This prostaglandin has 
been shown to prevent the accumulation of PMN following intradermal administra-
tion of LTB^.1"7 The information with respect to the release of lipoxygenase prod-
ucts following ultraviolet irradiation is rather scanty; however, a five-fold increase 
of dermal lipoxygenase activity has been shown in vitro in the skin of PUVA-
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treated mice. 1 8 It is of interest that normal human dermis metabolites arachidonic 
acid mainly to 15-hydroxyeicosatetraenoic acid1 9 which has recently been shown 
to inhibit the LTB^-induced Chemotaxis of PMN in vitro.2 0 
Several authors have reported that the aggregation of PMN and the adhesion of 
these cells to the endothelial cells are induced by mediators of inflammation, in­
cluding L T B * . 2 1 · 2 2 An effect of both UVB and PUVA therapy on the micro-
morphological appearance of the endothelial cells has been established.23 Theoreti­
cally, chronic damage of the endothelial cells might be accompanied by a reduced 
adhesion of PMN followmg standardized injury or epicutaneous application of LTB.». 
In conclusion, the most likely explanations for the UVB and PUVA-induced inhibi­
tion of the transepidermal migration of PMN may be the release of eicosanoids, 
counteracting the effect of LTB*, or interference at the level of the capillaries. 
The dramatic reduction of trauma- and LTB*- induced PMN accumulation following 
PUVA and UVB seems compatible with their effectiveness as maintenance thera­
p y . 2 4 · 2 5 Further studies to assess the duration of the suppression of PMN migration 
following treatment with PUVA and UVB would be worthwile. 
Several totally different therapies for psoriasis have been shown to inhibit LTB*-
induced PMN accumulation in vivo: methotrexate7·26, etretinate2 7, topical cortico­
steroids1 4, and UVB and PUVA as shown in the present study. Therefore, we may 
reasonably conclude that reduction of the transepidermal migration of PMN plays 
a central role in the therapeutic regression of psoriasis lesions. 
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Intra-epidermal accumulation of polymorphonuclear leuko-
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ABSTRACT 
Six patients with persistent palmoplantar pustulosis were treated with acitretin, 
and the clinical response was compared to the effect on the intra-epidermal ac-
cumulation of polymorphonuclear leukocytes (PMN). A prompt improvement of 
pustule formation and subsequently decreased scaling and erythema was seen in all 
patients. Following discontinuation of therapy, a relapse occurred within 2 weeks. 
With dosages of 45 or 55 mg/day, the clinical scores were only slightly better 
than with 25 or 35 mg/day. 
In patients using 25 mg acitretin a day, the leukotriene B^-induced intra-epidermal 
accumulation of polymorphonuclear leukocytes was not affected. However, a dosage 
of 35 mg/day resulted in a significant inhibition of PMN accumulation, dosages of 
45 and 55 mg/day causing an even more pronounced inhibition of this process. 
Although the effect of different dosages of acitretin is not clearly expressed in 
the severity scores, the dose-dependent effect on PMN Chemotaxis in vivo might 
be of relevance when combination therapies are considered, in order to achieve a 
complete clinical clearance. (Received February 19, 1988) 
PCM van de Kerkhof, Department of Dermatology, University of Nijmegen, Java-
straat 104, 6524 MJ Nijmegen, The Netherlands. 
INTRODUCTION 
Etretinate is a standard treatment for persistent palmoplantar pustulosis (PPP). 
For this condition, daily dosages of 1 mg/kg body weight have been advised.1"4 
An inverse relationship has been shown between the dosage of etretinate and the 
leukotriene B* (LTB^-induced accumulation of polymorphonuclear leukocytes 
(PMN)·5 
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The ethyl ester etretinate is hydrolysed in the body to form the acid derivate 
acitretin (Ro 10-1670). Due to accumulation of the ethyl ester in fatty tissue, the 
terminal elimination half-life proved to be more than 80 days for etretinate but 
only 2 days for acitretin.6 Therefore, from a pharmacokinetic point of view, acitre-
tin is much more easily manageable with respect to the teratogenetic properties of 
these drugs. In psoriasis and PPP, a beneficial effect of acitretin has been de-
scribed.7-9 However, the optimal dosage has not yet been established. 
In the present investigation, we report on the clinical response to acitretin in 6 
patients with PPP. In order to further elucidate the dose-response relationship in 
these variants of psoriasis, the effect of this drug on the LTIU-induced intra-
epidermal accumulation of PMN was measured. This model constitutes a reproducible 
method of investigating Chemotaxis of PMN in vivo, using the dermis and epidermis 
as a natural diffusion chamber.10·11 
PATIENTS AND METHODS 
Informed consent was obtained from 6 patients (5 females and 1 male). They were 
suffering from invahdating PPP. The mean age of the patients was 50.5 ± 7.0 years 
(± SD). No treatment for the pustulosis had been given 2 weeks before starting 
acitretin. One patient was treated with etretinate up to 1 month before starting 
acitretin; the other patients had been without systemic treatment for at least 6 
months. 
The total duration of the trial was 6 months. Before treatment and at monthly 
intervals, patients were monitored for clinical efficacy and side effects. The clinical 
score was recorded on a 0-4 scale for the individual symptoms (pustulation, ery-
thema, scaling), and sequential photographic documentation was carried out. Patients 
were interviewed regarding side effects, using a standardized record sheet. Before 
and at various time intervals during treatment, blood parameters were examined, 
including blood cell count, haemoglobin, bilirubin, urea, Creatinin, glucose, alkaline 
phosphatase, transaminases, cholesterol and triglycerides. Before and after 6 months 
of treatment, X-ray examination of the vertebral column was carried out. During 
the first 4 weeks, the dosage was 35 mg/day in all patients. Thereafter, the dosage 
was adjusted according to maximum acceptabihty, based upon objective and/or 
subjective side effects, with an upper limit of 60 mg a day. 
LTB.» challenge, with subsequent quantification of PMN, was carried out imme-
diately before and at regular intervals during treatment with acitretin (after 1 
month, 4 months and at the end of the trial). LTB* was obtained from Paesel 
GmbH, Frankfurt, Germany, and challenge was performed as described previously.11 
Aliquots of 10 ng LTB* in ethanol were applied via glass cylinders (5.5 mm dia-
meter) to the symptomless skin on the upper back. Ethanol was evaporated under 
a stream of nitrogen. Test sites were covered with impermeable dressings (Silver 
Patch, van der Bend, Brielle, The Netherlands). After 24 h, the dressings were 
removed and a biopsy was taken, using a razor blade provided with a metal guard. 
The biopsies were processed for elastase measurements, as described by Lammers 
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et a l . 1 2 Biopsies were washed thoroughly in phosphate buffered saline, weighed, 
homogenized in cetrimide buffer and centrifuged. Using the fluorogenic substrate 
MeOSuc-Ala-Ala-Pro-Val-N-methylcoumarin, elastase activity was measured in the 
supernatant fractions. After correction for endogenous inhibiting activity, the 
number of PMN per 10 μg skin was calculated from the fluorescence intensity. 
RESULTS 
Clinical response and evaluation of side effects 
After one month of treatment, pustulation had already decreased in 5 out of 6 
patients, whereas erythema and scaling responded more slowly. Fig. 1 shows the 
average scores for the patients who tolerated a gradual increase of the dosage 
( > 35 mg/day) and for those patients who could not tolerate these high dosages. At 
the end of treatment, the clinical scores for pustulation and scaling tended to be 
slightly better for the high-dosage group. Within 2 weeks following discontinuation 
of acitretin, a relapse was seen in all patients. 
AJ] patients except one tolerated an initial dosage of 35 mg/day during the first 
month. In 2 patients, the dosage could be increased up to 45-55 mg. However, in 
2 patients the dosage had to be reduced to 25 mg/day. Mucocutaneous discomfort 
was experienced by 6 patients: dry lips (4 patients), dry skin and pruritus (1 
patient) and hair loss (1 patient, discontinuing acitretm for this reason after 3 
months of treatment). In 2 patients, a transient increase of triglycerides was seen, 
and 2 patients showed increased transaminases. In one of these cases, liver func­
tions reverted to normal values during acitretin treatment. However, in the other 
patient liver function tests did not normalize and acitretin was discontinued after 
5 months of treatment. In this patient histological examination of a liver biopsy 
revealed a seronegative active hepatitis. 
Effect on intra-epidermal accumulation of PMN 
Although the clinical scores of low-dose treatment did not differ dramatically from 
the scores with high-dose treatment, the LTB^-induced PMN accumulation appeared 
to be dose dependent. After 1 month of treatment with acitretin, the values of 
LTB-»-induced PMN accumulation averaged 47% of the values observed immediately 
before treatment. In those patients who did not tolerate a further increase in the 
dosage, these values remained constant after 4 months and 6 months of treatment 
with acitretin. If the PMN accumulations at different time intervals of treatment 
are pooled, a marked dose dependency is seen (Fig. 2). Patients using 25 mg acitre­
tin had baseline values for PMN accumulation. After being treated with 35 mg of 
acitretin, LTB* applications resulted in reduced PMN accumulation compared with 
the levels before treatment (p < 0.01, Wilcoxon ranking test). After being treated 
with 45 mg or 55 mg of acitretin, LTB^ applications resulted in a further reduction 
compared with the reduction already achieved by a dose of 35 mg. 
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DISCUSSION 
The present study confirms the efficacy of acitretin for the treatment of PPP. 
Kingston et al. have documented a marked improvement of this disorder on treat-
ment with acitretin.0 Geiger et al. and Lassus et al. also reported a beneficial 
effect of acitretin in patients with severe psoriasis and some patients with pustular 
manifestations.7·8 In accordance with these previous observations, complete clearing 
was not observed in our patients. Since a combination of etretinate with PUVA 
therapy has been claimed to yield a complete remission in 100% of the patients13, 
the combination acitretin-PUVA might also result in total remission. 
A remarkable observation is the rapid relapse in all patients within 2 weeks after 
discontinuing acitretin. In contrast, treatment with etretinate is followed by much 
longer remission periods. Lassus et al. reported an average remission period of 6.3 
± 2 weeks following discontinuation of treatment with etretinate in PPP.3 Therefore, 
the relatively short terminal half-life of acitretin is presumably of relevance not 
only with regard to the teratogenicity of the drug, but it also appears to influence 
the duration of the clinical effect. 
The undesired clinical manifestations observed in the present series were all tran-
sient, except for the one case of hepatitis. Although this hepatitis may merely 
represent a coincidence, at this point in time we cannot rule out with certainty a 
causal relationship. Hepatitis during treatment with etretinate has been re-
ported.1*·15 However, serial liver biopsies in patients treated with etretinate so 
far failed to show significant abnormalities.10"13 
After 6 months of treatment, the clinical scores of the patients treated with 
increasing dosages (up to 45 and 55 mg/day) were slightly better than those of 
the patients treated with dosages between 25 and 35 mg/day. The study of Lassus 
et al. suggests that dosages of 25 mg/day and 50 mg/day have an equal effect on 
psoriasis, whereas a dosage of 10 mg/day had an effect intermediate between the 
high dosages and the placebo.3 The optimal dosage of acitretin in the treatment 
of pustulosis of palms and soles and psoriasis has not yet been established. 
The clinical assessment is qualitative and can easily be confused by subjective 
interpretations. Therefore, in the present study the effect of acitretin was assessed 
using the in vivo model for pustule formation: i.e. the intra-epidermal accumulation 
of PMN following epicutaneous application of a standard dose of LTIU. The model 
permits objective quantification of PMN accumulation in skin which is the fun-
damental process for PPP. In this in vivo model, acitretm at a dose of 25 mg/day 
did not have a significant effect, whilst 35 mg/day caused a significant inhibition 
of PMN accumulation and 45 mg or 55 mg/day caused a larger inhibition of this 
process compared to a dose of 35 mg. This difference was not clearly expressed in 
the clinical scores; however, the enhanced efficacy of higher dosages of acitretin 
on PMN accumulation in skin may be of relevance if complete clearing is aimed 
for, by prolonged treatment or combination therapy. 
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SUMMARY 
The transepidermal migration of polymorphonuclear leukocytes (PMN) is a well 
established target for antipsoriatic therapies. Tetracycline, although inhibiting the 
movement of PMN, is not an effective treatment for psoriasis. 
In contrast to the inhibition of PMN chemotactic response to serum and bacterial 
products, the leukotriene Ba-induced and trauma-induced intra-epidermal accumula-
tion of PMN was unaffected by tetracycline. 
INTRODUCnON 
The intra-epidermal accumulation of polymorphonuclear leukocytes (PMN) is one of 
the earüest and perhaps most characteristic constituents of the psoriatic lesion.1 
In order to study the interference of drugs with the dynamics of this process 2 
experimental models are available. The intra-epidermal accumulation of PMN fol-
lowing sellotape stripping is the response to a standardized endogenous release of 
mediators of inflammation.2 The intra-epidermal accumulation of PMN following 
epicutaneous application of leukotriene B* (LTEU) is another reproducible model, 
in which a standardized exogenous stimulus is given.3··* Etretinate, acitretin, metho-
trexate, phototherapy, photochemotherapy, dithranol and topical corticosteroids -
although strikingly different therapeutical approaches - share 2 characteristics: a 
well established antipsoriatic effect clinically and a profound inhibition of intra-
epidermal accumulation of PMN in these models.'*"10 
Tetracyclines have been reported to interfere with PMN functions in vitro and in 
vivo.11"14 Surprisingly, these drugs are not part of the repertoire of antipsoriatic 
therapies. However, as far as we know, the LTB^-induced PMN accumulation has 
never been reported to be inhibited by tetracyclines. In the present investigation 
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the interference of an oral course of tetracycline with the trauma- and LTB*-
induced intra-epidermal accumulation of PMN was studied. 
MATERIALS AND METHODS 
Nine subjects without signs or previous history of skin diseases participated in 
the study. The group consisted of 2 females and 7 males, aged between 22 and 
35 years. No subject had received any medication for at least 3 months prior to 
the study. Prior consent of the Medical Ethics Committee was obtained for these 
experiments. The volunteers received an oral course of tetracycline in doses of 
250 mg four times a day for 10 consecutive days. One day before initiation of the 
therapy, and on the 3rd and 10th day of the treatment, LTB* was applied and 
sellotape stripping was carried out. 
LTB* was purchased from Paesel GmbH Frankfurt, Germany. Aliquots of 10 ng 
L T m in ethanol were applied in 10 pi droplets through glass cylinders (diameter 
5.5 mm) on the upper back skin and ethanol was evaporated under a stream of 
nitrogen.3·* Application sites were marked with eosin and covered with impermeable 
dressings (Silverpatch, Van der Bend, Brielle, The Netherlands). At the same time 
circular areas (diameter 15 mm) were stripped on areas at least 10 cm from the 
LTB* sites by repeated applications of sellotape. Removal of the stratum corneum 
was considered complete when the whole area appeared to be glistening (30-40 
applications). Biopsies were taken from the stripped areas and from the LTB^ 
treated sites 8 h and 24 h after these challenges, respectively. No anaesthetic agent 
was employed. All specimens were cut freehand, using a razorblade in conjunction 
with a metal guard. The biopsies (fresh weight 2-3 mg, approximately 3 mm diameter 
and 0.2 mm thick) were processed for elastase measurement. 
Analytical procedures were as described previously.2·15 In brief, the biopsies were 
rinsed thoroughly in phosphate buffered saline, homogenized in buffer containing 
cetrimide and centrifuged. Elastase activity of the supernatant was determined by 
measuring the fluorescence of 4-methyl-7-aminocoumarin, released from the sub­
strate MeOSuc-Ala-Ala-Pro-Val-N-methylcoumarin; endogenous inhibition was cor­
rected for by the inclusion of an internal standard of elastase (equivalent to 500 
PMN). The density of infiltrating PMN per 10 μg skin was calculated using the 
value of 0.66 pmol 4-methyl-7-aminocoumarin released per hour per PMN. 2 
Statistical evaluation was performed using the Wilcoxon rank test for paired sam­
ples. 
RESULTS 
Tetracycline in dosages of 1 g a day were well tolerated by all the subjects. Only 
one of them had experienced a mild gastrointestinal discomfort on days 9 and 10 
of the treatment period. 
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PMN accumulations 8 h following sellotape stripping and 24 h following the applica­
tion of LTB-t before and during treatment with tetracycline are shown in Figs 1 
and 2. Both trauma- and LTB^-induced PMN accumulations were unaffected by 
tetracycline (p > 0.05). The percentage inhibition of a standard preparation of 
elastase by all the skin biopsies examined was 13 ± 1.5% (mean ± SEM) and no 
statistically significant difference could be shown from the inhibitory activity of 
12 ± 4.0% reported for normal unchallenged skin15 (p > 0.05). 
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DISCUSSION 
The present investigation clearly shows that an oral course of tetracycline in a 
dosage of 1 g a day does not inhibit the trauma- or LTB^-induced intra-epidermal 
accumulation of PMN. 
The chemotactic response of PMN to human serum, Cs
a
, bacterial endotoxins and 
Az influenza virus have been shown to be inhibited by tetracycline.11-14 To the 
best of our knowledge no data are available in the literature regarding a possible 
interference of this drug with the chemotactic response of PMN to inflammatory 
eicosanoids. 
The molecular basis of the interference of tetracycline with PMN Chemotaxis is 
not clear. It has been suggested that the interference is not at the level of the 
PMN themselves but comprises an inhibition of the generation of chemotactic 
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factors and binding to chemoattractants.11 However, a more recent study indicates 
that a direct interference with the PMN movement occurs as well.13 
In contrast to the observations in the present study tetracycline has been reported 
to inhibit the potassium iodide-induced intrafoUicular micropustule formation.10 An 
explanation for this discrepancy might be a different bioavailability in these models. 
Tetracyclines have been reported to occur in relatively high concentrations in the 
follicular epithelium.17 However, using skin chambers with serum complement and 
bacterial culture supernatants as chemoattractants, tetracycline inhibited the PMN 
Chemotaxis.18 Combining the present study with these observations using skin 
chambers it seems feasible that tetracycline does not affect the chemotactic re-
sponse of the whole repertoire of chemoattractants. 
A selective interference of tetracycline with PMN Chemotaxis is in line with the 
available data on the role of PMN as a target for antipsoriatic therapies. Although 
some authors suggest an effect of tetracycline in pustular psoriasis,19·20 this drug 
has by no means an established reputation as treatment for this disease The 
negative effect of tetracychne on the LTB*- and trauma-induced PMN accumulation 
is compatible with the essentially negative clinical results of tetracycline in pso-
riasis. 
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ABSTRACT 
Biopsies were removed from the margin of plaques in 11 untreated psoriatic patients, 
and 8 μιη sections prepared using the cryostat. Altemate sections were stained 
with H and E to assess the accumulation of polymorphonuclear leukocytes. The 
remaining sections were stained with the monoclonal antibody КІ67 in order to 
determine the number of cycling epidermal cells. 
In areas where polymorphonuclear leukocytes occurred in the stratum Malpighii 
the number of cycling epidermal cells was relatively low. In contrast, a positive 
correlation was shown between the density of microabscesses of Munro and the 
number of cycUng epidermal cells. 
The clinically uninvolved skin of psoriatic patients shows a moderate enhancement 
of epidermal growth in the absence of any infiltrate. In the lesionai skin the 
recruitment of cycling epidermal cells does not coincide with the invasion of 
polymorphonuclear leukocytes into the epidermis, but rather follows the penetration 
of these cells. Key words: polymorphonuclear leukocytes, epidermal proliferation, 
psoriasis. 
INTRODUCTION 
In the clinically uninvolved skin of psoriatic patients several parameters for epider­
mal growth are increased such as labeling index, mitotic counts, percentage cells 
in S phase.1-5 No infiltrate occurs in the symptomless skin of the patients. 
Increased recruitment of cycling epidermal cells and intra-epidermal accumulation 
of polymorphonuclear leukocytes (PMN) are characteristic features of the psoriatic 
lesion.5·6 PMN invade the epidermis of the psoriatic lesion and form micropustules 
of Kogoj, which are located in the stratum Malpighii and in a later stage form 
intracorneal microabscesses of Munro.7 The margin zone of the psoriatic plaque is 
of great pathogenetic interest as lesions grow by centrifugal expansion. In this 
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zone the order of events is not clear. Some authors have proposed that epidermal 
proliferation precedes inflammation8 but more recent work suggests that inflamma­
tion is primary to epidermal proliferation.9 
In order to find out whether epidermal proliferation and invasion of PMN are 
related or independent processes, both phenomena were quantified in the margin 
zone and correlation studies were carried out. 
PATIENTS AND METHODS 
Eleven patients, 5 males and 6 females, aged between 20 and 70 years, participated 
in this study. All patients had a plaque psoriasis of many years' duration and had 
been without treatment for at least 2 weeks. The extent of the lesions varied 
between 3 and 15% of the body surface. Six of them had experienced spreading of 
the lesions during the last 4 weeks and 5 did not notice any change in their lesions 
during this period. 
Four-millimeter punch biopsies were taken from the margin of a psoriatic plaque 
in each patient, following infiltration with a local anaesthetic agent (Xylocaine 1% 
+ adrenalin 0.001%). The biopsy site was the utmost periphery of the lesion just 
inside the clinical boundary between involved and uninvolved skin. Biopsies were 
inbedded in OCT compound (Miles Laboratories Inc., Ind., USA) and stored in liquid 
nitrogen. 
Biopsies were processed for sequential cryostat-sectioning (8 μιη). On alternating 
sections (uneven numbers) Η and E staining was done using standard procedures, 
in order to assess accumulation of PMN. On the remaining sections (even numbers) 
immunohistochemical staining with the monoclonal antibody КІ67 (Dakopalts, Copen­
hagen, Denmark) was carried out, in order to assess proliferative activity of the 
epidermis. The monoclonal antibody КІ67 binds to a nuclear antigen expressed by 
cycling cells only. 1 0 · 1 1 In normal skin and symptomless skin of psoriatic patients 
cytoplasmic expression of a 'КІ67 antigen-like' substance occurs with sporadic 
nuclear staining. The immunostaining described by these authors was used with 
minor modifications. In brief, fixation was carried out in acetone/ether (60/40 
v/v%) for 10-20 min. Air-dried sections were then incubated for 3-5 min in PBS 
containing 0.01% Tween 80, and subsequently incubated with КІ67, diluted 1:5 in 
PBS, for 30 min at room temperature in a moist chamber. After washing in PBS a 
peroxidase-conjugated rabbit antimouse antibody (Dakopatts, Copenhagen, Denmark) 
was added at a dilution of 1:25 in PBS containing 5% human AB serum. The bound 
peroxidase was developed with the S-amino-Ç-ethylcarbazole/HzOz reaction for 20 
min. Finally sections were counterstained with Mayer's hematoxylin and mounted 
in glycerine gelatine. This method has been shown to give satisfactory results in 
the lesions of various skin disorders." 
In sections stained with H and E, the numbers of micropustules of Kogoj (defined 
as accumulations of PMN in the stratum Malpighii) and microabscesses of Munro 
(defined as accumulations of PMN in the stratum corneum) were counted in 40 fields 
of 1 mm. However, the large-sized microabscesses are overrepresented by the ap-
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proach of taking alternate sections. Therefore an estimate was made of the sizes 
of microabscesses and micropustules: accumulations of less than 10 PMN were rec­
orded as 'small-sizedX ± ), accumulations between 10 and 25 PMN as 'medium-sized' 
( + ) and larger accumulations as 'large-sized'( + + ). On the sequential sections stained 
with КІ67, 40 fields of 1 mm diameter were scanned for positive nuclei. The topo­
graphic relation between PMN accumulations and density of Ki67-positive nuclei 
was studied. 
Linear regression analysis was carried out between the density of PMN accumula­
tions and Ki67-positive nuclei. 
A Wilcoxon ranking test was used for statistical evaluation of КІ67 expression in 
patients without or with only small-sized microabscesses and patients with medium-
to large-sized microabscesses. 
RESULTS 
In the total group of 11 patients the infiltration of PMN occurred as microabscesses 
of Munro or as micropustules of Kogoj. In 2 patients no microabscesses were found, 
in 4 patients only small-sized microabscesses and in 5 patients also medium- and 
or large-sized microabscesses were seen. Micropustules were observed in 4 patients: 
in 2 patients small-sized and in 2 patients medium- to large-sized. Ki67-positive 
nuclei occurred in the basal and suprabasal compartment. The range for КІ67-
positive nuclei per millimeter biopsy length was 151 ± 50 (mean ± SD) for the 
total group. Fig. 1 illustrates examples of mild and profound expression of КІ67. 
The relation between Ki67-positive nuclei and microabscess formations is indicated 
in Fig. 2. A statistically significant correlation could be shown between КІ67-
positive nuclei and the number of microabscesses (r = 0.798; ρ < 0.005). A statisti­
cally significant difference as to Ki67-positive nuclei could be shown between 
patients without or with only small-sized microabscesses and patients with medium-
and/or large-sized microabscesses (p < 0.005). 
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Fig. 1. Expression of Ki67-positive nuclei. Examples of nuclear staining are indicated 
by a filled arrow, examples of cytoplasmatic staining by an open arrow (\ 240). 
(a) A mild expression (36 nuclei/mm). 
(b) A heavy expression (164 nuclei/mm). 
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Fig. 2. Relationship between Ki67-positive nuclei and microabscess formation. 
(a) Number of microabscesses/mm. 
(b) Size of microabscesses. 
0 or ± = no microabscesses or small-sized microabscesses only; 
+ or + + = also medium- and or large-sized microabscesses. Bars represent means 
± SD. 
In 2 patients medium- to large-sized micropustules were observed. In these areas 
the number of Ki67-positive nuclei was markedly reduced, averaging 50 and 55% 
of the mean values observed in 40 1-mm fields in the same biopsies. Fig. 3 illus-
trates a micropustule of Kogoj and КІ67 expression in this area. 
DISCUSSION 
Both a reduction of cell cycle time and an enhanced recruitment of resting cells 
(Go cells) to cycling cells have been incriminated as mechanisms of epidermal 
hyperproliferation. Recently, evidence is accumulating that the latter is actually 
the case in the psoriatic lesion.5 Therefore the visualization of cycling cells by 
the monoclonal КІ67 is a rational approach for the quantification of the rate of 
production of keratinocytes. The method is easily applicable for a laboratory with 
facilities for immunohistochemistry. 
As abnormalities in epidermal growth have been demonstrated in the symptomless 
skin of the patients without any infiltrate, the PMN is not a conditio sine qua 
non for hyperproliferation in psoriasis. However, the recruitment of cycling cells 
indicated by КІ67 expression is restricted to the psoriatic lesion. In areas where 
PMN penetrated the basal cell layers and formed micropustules of Kogoj, a markedly 
decreased number of cycling cells was shown in comparison to the overall picture 
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F/g. 3. Ki67-positive nuclei within an area of micropustule formation (x 240). 
(a) H and E staining; (b) КІ67 staining on the adjacent section. 
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of the corresponding biopsy. Although the keratinocytes may be damaged by the 
invading PMN, it is unlikely that the decreased staining is the direct result of 
such, as we are dealing with a nuclear staining. Therefore, the present investigation 
suggests that recruitment of Go cells is induced whilst PMN are moving through 
the epidermis on their way to the stratum corneum. Indeed a positive correlation 
between density or size of microabscesses of Munro and number of cycling epider-
mal cells could be shown. This relation is compatible with a causal link between 
these processes: invading PMN triggering epidermal proliferation. On the other 
hand a common metabolic control of both processes with a more immediate effect 
on PMN Chemotaxis and a delayed effect on epidermal proliferation could be of 
relevance. In this respect a role has been postulated for the phosphoinositol cycle, 
regulating both epidermal growth and the release of inflammatory eicosanoids.13 
Stimulation of animal skin with phorbol esters showed a similar dynamics to that 
observed in the margin zone: first accumulation of PMN which is compücated 24 h 
later by epidermal proliferation.14 
In a previous investigation the accumulation of PMN was quantified in the central 
zone of the lesions of patients with chronic stable plaque psoriasis; only 12 out of 
29 biopsies showed accumulation of PMN.15 In contrast, the present study revealed 
that intra-epidermal accumulation of PMN was substantial in biopsies from the 
marginal zone in all patients with chronic stable plaque psoriasis, which suggests 
that PMN play a significant role in the margin zone. Comparison of the numbers 
of Ki67-positive nuclei in the epidermis of the margin zone (151 ± 50 nuclei/mm) 
with numbers in the central zone (196 ± 59 nuclei/mm)10 revealed no significant 
difference. DNA measurements with flow cytometry also failed to show a significant 
difference between the margin zone and central areas.2 Therefore in the central 
zone of the fully developed lesion epidermal hyperproliferation remains whereas 
PMN invasion is less prominent compared to the margin of the lesion. At a first 
glance this discrepancy seems not compatible with a major role of the PMN in the 
maintenance of the lesion. However, the psoriatic lesion is a dynamic process. 
Intra-epidermal penetration of PMN is a cyclic phenomenon which occurs sporadi-
cally in 'hot spots' of the central zone. In this respect it is of interest that 
following leukotriene B*- induced microabscess formation, epidermal hyperprolifera-
tion persisted for 72 h after disappearance of PMN.1-7 Therefore it is feasible that 
epidermal proliferation in the central zone of the psoriatic plaque is the conse-
quence of previous PMN invasion. 
In conclusion, although epidermal proliferation is not restricted to areas with in-
vading PMN, the present study suggests a link between recruitment of cycling epider-
mal cells and invasion of PMN into the epidermis. The penetration of PMN into the 
epidermis anticipated the recruitment of cycling epidermal cells. This recruitment 
became evident at the moment the PMN had reached the stratum corneum. 
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ABSTRACT 
Elastase inhibiting activity (EIA) has been observed in normal skin as a response 
to surface trauma, immediately following the intra-epidermal accumulation of poly-
morphonuclear leukocytes (PMN). In order to elucidate the relation between EIA 
and inflammation, the inhibiting activity was assessed in skin samples of scaling 
dermatoses (a) without significant inflammation: erythrodermic autosomal recessive 
lamellar ichthyosis (EARLI), non-erythrodermic autosomal recessive lamellar ichthy-
osis (NEARLI), X-linked recessive ichthyosis (XLRI) and X-linked dominant chondro-
dysplasia punctata (XLD-CDP); (b) with predominantly mononuclear cell infiltration: 
atopic dermatitis; (c) with mixed infiltration of PMN and mononuclear cells: psoriasis 
and Netherton syndrome. 
All skin disorders investigated showed an increased EIA as compared to normal 
skin. Scales from psoriatic lesions, EARLI and Netherton syndrome showed a statis-
tically significant increase in EIA above that observed in other monogenic disorders 
of keratinization NEARLI, XLRI, XLD-CDP and above atopic dermatitis. 
EIA proved to be an indicator for abnormal keratinization with a marked expression 
when a mixed infiltrate is present in the skin. Key words: Elastase inhibiting 
activity; polymorphonuclear leukocytes; scaling dermatoses. 
A. Chang Department of Dermatology, University Hospital Nijmegen, Philips van 
Leydenlaan 25, 6525 EX Nijmegen, The Netherlands. 
INTRODUCnON 
Human polymorphonuclear leukocytes (PMN) contain the proteolytic enzyme elastase, 
which is unique and specific for these cells.1·2 Briggaman and coworkers suggested 
that elastase might disrupt the dermo-epidermal junction in order to permit the 
penetration of PMN into the epidermis.3 
Inhibiting activity directed against elastase has been demonstrated in the epidermis 
of normal skin immediately after the transepidermal migration of PMN induced by 
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surface trauma.4 Therefore it is attractive to hypothesize that the presence of elas-
tase inhibiting activity (EIA) might be indicative for an acute infiltrate with PMN. 
The aim of the present study was to elucidate further the role of EIA in inflam­
mation in a variety of scaling skin disorders. The spectrum of diseases included 
disorders of keratinization without significant inflammation, scaling skin disorders 
with a predominantly mononuclear infiltrate and disorders of keratinization with a 
mixed infiltrate of mononuclear cells and PMN. EIA was quantified in scales and 
biopsies of lesionai skin. 
PATIENTS AND METHODS 
Patients 
A total of 34 patients with a variety of disorders of keratinization were included 
in the study. The monogenic disorders of keratinization comprised: erythrodermic 
autosomal recessive lamellar ichthyosis (EARLI, η = 5), non-erythrodermic autosomal 
recessive lamellar ichthyosis (NEARLI, η=6), X-linked recessive ichthyosis (XLRI, 
η = 4), Netherton syndrome (η = 3), and X-linked dominant chondrodysplasia punctata 
(XLD-CDP, n = 3). For the purpose of comparison, the following polygenic disorders 
characterized by inflammation and scaling were included: psoriasis (n = 6) and atopic 
dermatitis (n = 7). 
Diagnosis was established by clinical and histological criteria. Patients had not 
used any therapy for at least 1-2 weeks before collecting specimens. As controls, 
18 healthy volunteers participated in the study. 
Sampling procedure 
Scales were collected from the clinically involved skin of all patients. The scales 
were taken from various regions of the body with the exception of the palms, the 
soles and the head. In 6 healthy controls normal stratum comeum was collected 
from the back by gentle scraping with a scalpel blade. From 6 other healthy 
volunteers scrapings of normal callus were obtained from the feet. Bleeding was 
avoided during collection of scales and scrapings. 
Keratotome biopsies (Castroviejo) were taken from the clinically involved skin of 
6 psoriatic patients and in 3 of them from the symptomless skin at least 20 cm 
from the adjacent lesion. In 6 healthy controls keratotome biopsies were taken 
from the skin on the back. For biopsies from lesionai skin the setting for depth 
was 0.3 mm and for the non-lesional skin 0.2 mm. 
Scales and biopsies were stored at -20oC prior to analysis. 
Analytical procedures 
Scales and biopsies were processed for determination of EIA as described pre­
viously.4·5 In brief, biopsies were rinsed in phosphate buffered saline, and all 
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samples were homogenized at appropriate concentrations in buffer containing 
cetrimide (0.3% cetrimide, 0.1 M Tris, IM NaCl; pH 8.5) and centrifuged (15 min, 
35,000 g). Serial dilutions were made from the clear supernatant and a standard 
preparation of elastase (1 ng enzyme, equivalent to 500 PMN) was added. Elastase 
activity was measured as the release of the fluorescing product (4-methyl-7-amino-
coumarin) from the fluorogenic substrate MeOSuc-Ala-Ala-Pro-Val-N-methyl-
coumarin. 
Inhibition of the elastase preparation was determined for every sample dilution 
with the following formula: 
Percentage inhibition = j 1 - — ^— J χ 100 
where E sample = elastase activity with sample 
E max = elastase activity without sample 
EIA is expressed as the weight of the sample ^ g ) required for 50% inhibition of 
the standard elastase preparation under the experimental conditions described. 
Statistical analysis 
Statistical evaluation was carried out using the Wilcoxon ranking test for 2 indepen­
dent samples. 
RESULTS 
The EIA of biopsies from lesionai and non-lesional psoriatic skin are given in Fig. 
1. A highly significant increase in EIA was observed for the psoriatic lesions 
compared to the skin of normal volunteers (p < 0.005). EIA in clinically uninvolved 
skin of psoriatic patients was in the range of healthy volunteers. 
The EIA of" scales from disorders of keratinization are given in Fig. 2. EIA in 
scales of psoriatic lesions was higher compared to that in stratum corneum from 
normal volunteers (p < 0.005). Compared to the inhibition in biopsies, scales from 
psoriatic lesions showed an even greater EIA. Plantar callus also showed an in­
creased EIA compared to the activity in normal stratum corneum from healthy 
volunteers (p < 0.005), however the inhibition was less than that observed for 
psoriatic scales. Scales obtained from monogenic disorders of keratinization without 
inflammation, and from atopic dermatitis were characterized by EIA of the same 
order of magnitude as normal callus. In contrast, 2 monogenic disorders of kera­
tinization (Netherton syndrome and EARLI) with inflammatory changes showed 
pronounced EIA in the same range as scales from psoriatic lesions. 
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Fig. 2. Individual elastase inhibiting activity in 
scrapings of normal skin and callus and scales of 
several dermatoses. Units as in Fig. 1. 
XLRI = X-linked recessive ichthyosis; NEARLI = 
non-erythrodermic autosomal recessive lamellar 
ichthyosis; XLD-CDP = X-linked dominant chon­
drodysplasia punctata; EARLI = erythrodermic 
autosomal recessive lamellar ichthyosis. 
DISCUSSION 
The present study demonstrates that scales of various scaling skin disorders display 
some EIA, whereas pronounced EIA occurs in inflammatory conditions. EIA in scales 
from psoriatic lesions was compared with EIA of keratotome biopsies from the 
lesions. It is of importance that EIA in the scales was even more marked than 
EIA in the biopsies, indicating that the topographical distribution of EIA is not 
limited to the dermis or viable layers of the epidermis but persists in the horny 
layer. The preservation of EIA in the horny layer may be explained by its remark­
able stability, one of the reported characteristics of EIA in psoriasis.0 
A slight but statistically significant inhibition was measured in scales of patients 
with some monogenic disorders of keratinization: XLRI, XLD-CDP and NEARLI. In 
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these disorders the abnormalities in the epidermis are not accompanied by a sig­
nificant inflammatory infiltrate.7 The magnitude of EIA was in the same range as 
EIA of normal plantar callus. Therefore, the induction of slight EIA might be an 
aspecific event in abnormal keratinization. 
Scales of chronic eczematous lesions of patients with atopic dermatitis also showed 
a moderate EIA, of the same order of magnitude as scales from the non-inflam­
matory disorders of keratinization. The inflammatory infiltrate in uncomplicated 
atopic dermatitis is mononuclear with an admixture of some eosinophils.8 This sort 
of infiltrate was not accompanied by an mduction of EIA above the range already 
reached by abnormal keratinization. 
However, scales of lesionai skin of patients with psoriasis, scales of patients with 
EARLI and scales of patients with Netherton syndrome showed a pronounced EIA. 
In psoriasis intra-epidermal accumulation of PMN is a classical feature in early 
and active phases of the disease.9 In the central zone of chronic stable lesions, 
intra-epidermal accumulation of PMN occurs in an intermittent cyclic pa t te rn . 1 0 · 1 1 
In Netherton syndrome the histological picture shows features similar to psoriasis 
with prominent PMN accumulation.12 In this syndrome capillary dilation is seen with 
PMN invading the epidermis with the formation of micropustules.13 Therefore 
infiltrates in which PMN participate seem to be associated with EIA levels well 
above that found in non-inflamed disorders of keratinization or atopic dermatitis. 
Scales from EARLI show a highly significant increase in EIA as compared to its 
non-inflammatory counterpart, NEARLI. Based on clinical, histological, cell-cycle 
kinetic and biochemical criteria (n-alkanes, lamellar body enzymes) differentiation 
between these two forms of autosomal recessive lamellar ichthyosis is possi­
b l e . 1 4 · 1 5 · 1 6 The present observation further substantiates the differences between 
EARLI and NEARLI from the point of view of inflammation control. The association 
between the marked EIA and the composition of the inflammatory infiltrate can 
only be speculative as the infiltrate present in EARLI has so far not been studied 
extensively. Although the histological picture of EARLI shows striking similarities 
to psoriasis,12 an intra-epidermal accumulation of PMN has not been reported. 
The source of EIA is unknown. However, the fact that EIA is slightly increased 
in scales of disorders of keratinization without any infiltrate present suggests 
that it is synthesized in the epidermis. The fact that EIA-induction does not 
coincide with, but has a delay with respect to intra-epidermal accumulation of PMN 
following standardized injury,3 also implies that EIA is not carried into the epider­
mis by PMN but rather is induced in the epidermis itself. 
The biochemical nature of EIA is not known. Preliminary characterization of the 
elastase inhibiting factor in psoriatic scales showed that we are dealing with a 
heat-stable, acid- and alkaline-stable substance with a molecular weight of ap­
proximately 10,000 Dalton.6 This elastase inhibitor does not inhibit human cathepsin 
G or bovine trypsin. The inhibition of human leukocyte elastase is stoichiometric 
and, assuming equimolar kinetics, the concentration of the inhibitor in psoriatic 
epidermis averages 25 μg/g. These properties suggest that the inhibitor described 
here is distinct from any previously reported antiproteinase.1 - 7·1 8·1 0 Further charac­
terization of elastase inhibitors in diseases with intra-epidermal invasion of PMN 
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is in progress. Pharmaceutical compounds with EIA might open a new way for treat-
ment of skin diseases in which intra-epidermal invasion of PMN is of significance. 
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SUMMARY 
Inhibiting activity towards polymorphonuclear leukocytes (PMN) elastase was found 
in biopsies of lesionai psoriatic epidermis taken from patients with chronic plaque 
psoriasis. Epidermis taken either from normal skin or from the uninvolved skin of 
psoriatic patients contained very low levels of inhibiting activity (1-2% compared 
to the psoriatic lesion). Large amounts of inhibiting activity were also found in 
scales from psoriatic patients, whereas scrapings of normal stratum corneum were 
practically devoid of inhibiting activity. Sephadex G-50 gel permeation chromato­
graphy of psoriatic scale extracts, used as source of inhibitor for biochemical 
characterization, showed 2 peaks of activity at about 10 and 20 kDalton. Human 
cathepsin G was not inhibited by the scale extract, whereas porcine pancreatic 
elastase was inhibited in the same manner as PMN elastase. Inhibitmg activity of 
scale or epidermal extracts was pH-stable and relatively heat-stable. Keratinocytes 
were shown to be most likely source of inhibitor in the epidermal extracts. We 
would hypothesize that the production of anti-elastase activity by human epidermis 
represents an, "off-switch" mechanism for the local inflammatory response or could, 
alternatively, be involved in the regulation of epidermal proliferation. 
INTRODUCTION 
PMN-derived proteases such as elastase and cathepsin G have the potential to 
cause tissue damage once they are secreted, since these enzymes are active at 
neutral pH and can use a broad spectrum of connective tissue molecules as sub­
strates.1 In order to control proteolysis by these enzymes, a number of highly 
effective proteinase inhibitors are present in the extracellular space.2 These pro­
teinase inhibitors are either systemically present such as alpha-l-proteinase inhibitor 
(alpha-1-PI) or they are locally synthesized such as antileukoprotease (ALP) in 
lungtissue.3 Local inactivation of alpha-1-PI in the lungs or escape of elastase 
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from inactivation by alpha-1-PI have been implied as mechanisms responsible for 
lung emphysema·* and cartilage destruction.5 No definitive role for PMN-derived 
neutral proteases has been demonstrated in human skin diseases. However, recently 
it was shown that PMN elastase and cathepsin G can degrade components of the 
epidermal basal lamina, thereby dissociating the epidermis from the dermis.6 In 
particular the epidermal compartment is likely to be exposed to proteolytic attack, 
since one would expect the levels of plasma proteinase inhibitors to be fairly low 
at this site compared to plasma or interstitial fluid, the epidermal basal membrane 
being a barrier for high molecular weight and negatively charged substances.7 
Indeed it was demonstrated that alpha-2-macroglobulin is virtually absent in normal 
human epidermis.8 The epidermal architecture would be at risk under conditions of 
PMN-infiltration such as psoriasis or epidermal inflammation in general. Several 
proteinase inhibitors0·1 0 have been described for human epidermis (see ref 11 for 
a review). There is, however, little information on inhibitors of PMN neutral 
proteases except for the reported presence of alpha-1-PI in normal human epider­
mis8, and to our knowledge no specific epidermal inhibitors for PMN elastase have 
been documented. In this chapter we present a preliminary biochemical characteriza­
tion of elastase-inhibiting activity in human epidermis as previously reported in 
chapters II and IX. The biological significance of these inhibitor(s) is discussed. 
METHODS 
Chemicals 
Methoxysuccmyl-alanyl-alanyl-propyl-valyl-7-amido-4-methylcoumarin (MeOSuc-Ala-
Ala-Pro-Val-AMC),N-succinyl-phenylalanyl-leucyl-phenylalanine-thiobenzylester(Suc-
Phe-Leu-Phe-SBzl) and N-a-benzoyl-DL-arginme-7-amido-4-methylcoumarin (Cbz-
Arg-AMC) were obtained from Bachern, Bubendorf, Switzerland. Cetyltrimethyl-
ammoniumbromide (СТАВ) was obtained from ICI, UK. Affigel-10 was obtained 
from Biorad laboratories, Richmond, Ca, USA. Sephadex G-50 (fine grade) was 
from Pharmacia fine Chemicals, Uppsala, Sweden. Dithio(bis)mtrobenzoic acid 
(DTNB), alpha-1-proteinase inhibitor (alpha-1-PI), phenylmethylsulphonylfluoride 
(PMSF), trypsin, porcine pancreatic elastase and phenylbutylamine were from Sigma 
Chemicals, St Louis, Mo, USA. Isoelectric focusing gels (pH range 3.5 to 9.5) were 
obtained from LKB Bromma, Sweden. 
Skin samples 
Biopsies were taken from psoriasis patients (stable chronic plaque psoriasis) and 
normal healthy volunteers, using either a razor blade in conjunction with a metal 
guard 1 2 or a Castroviejo keratotome. The keratome was set for 0.2 mm thickness 
for normal skin and 0.3 mm for lesions. An ethylchloride spray was used as anaes­
thetic agent. Biopsies were washed in phosphate buffered saline (PBS) and imme­
diately processed for extraction (see below). Epidermal scales from the clinically 
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involved skin of psoriatic patients was stored at -20oC until use. Normal stratum 
corneum was obtained from the backs of healthy volunteers by gentle scraping 
with a scalpel blade, and stored at -20oC until further use. 
Extraction of skin biopsies and scales 
Scales and biopsies were processed for determination of elastase inhibiting activity 
as described previously.13 In brief, biopsies were rinsed in PBS and subsequently 
homogenized in 100 mM Tris, 1 M NaCl, 0.3% СТАВ, pH 8.5 (= extraction buffer). 
For some purposes the material was extracted in PBS. The homogenates were 
centrifuged for 15 minutes at 35,000 g and the clear supernatant was stored at 
-20oC. 
Purification of PMN elastase and cathepsin G 
Elastase and cathepsin G were purified from PMN obtained by lymphapheresis of 
a patient with chronic myeloid leukemia. Briefly, myeloid cells were subjected to 
differential salt extraction (0.1 M NaCl to extract the bulk of elastase, and 1 M 
NaCl to extract the bulk of cathepsin G), and the enzymes were purified on a 
phenylbutyl-Affigel-10 affinity column.1*·13 Samples were dialysed against 1 M 
NaCl and stored at -20oC. 
Elastase assay 
Elastase was measured according to previously described methods10 using the 
fluorogenic substrate MeOSuc-Ala-Ala-Pro-Val-AMC.17 
Assay of elastase inhibiting activity 
Inhibition of elastase activity by skin samples was routinely measured as the 
percentage inhibition in a standard amount of elastase. A sensitive microassay16 
was used to enable measurement of small amounts of inhibiting activity. Briefly, an 
extract of 500 PMN (10 μΐ) equivalent to 1 ng human leukocyte elastase (cahbrated 
with purified active site titrated elastase, a kind gift of Dr. J. Kramps, Dept Lung 
Disease, University Hospital Leiden, The Netherlands), was mixed with inhibitor 
(10 μΐ) and incubated at ЗТС for 15 minutes to allow complexing of enzyme and 
inhibitor. Thereafter, 20 μΐ of substrate solution was added (250 μΜ in extraction 
buffer) and the reaction was allowed to proceed for 30 minutes at ЗТС. The 
incubation was terminated by the addition of 1 ml buffer (100 mM NazCOa, pH 
10.5) and fluorescence was measured at 375 nm (exitation) and 440 nm (emission). 
Inhibition of elastase activity in this assay was calculated as the percentage inhi­
bition of the original activity of 1 ng elastase (final concentration 1 nM). One unit 
of inhibiting activity was defined as the amount required to reduce the activity of 
1 ng elastase by 50%. Elastase activity was linear during the assay (substrate 
concentration 125 μΜ, of which less than 10% is converted during the 30 minute 
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incubation with 1 ng elastase). Inhibition of elastase activity by epidermal extracts 
was linear with the amount of inhibitor added, up to about 70% inhibition. 
Cathepsin G assay 
Cathepsin G was measured colorimetrically using Suc-Phe-Leu-Phe-SBzl as a sub­
strate and DTNB as a coupling reagent to detect the free benzylthiol, according 
to Harper et a l . 1 8 Inhibition of cathepsm G was measured by preincubating purified 
cathepsm G at 0.05 to 5 μg per ml (final concentration) with varying amounts of 
samples to be assayed for inhibiting activity, at 3TC, from 5 to 60 minutes. All 
incubations were performed in 1 M NaCl, 50 mM NazHPO*, pH 7.5. Thereafter the 
cathepsin G activity was measured and compared to the reference sample containing 
no inhibitor. Alpha-1-PI was taken as a positive control. 
Protein measurements 
Protein in the eluent of Sephadex G-50 chromatography was monitored at 280 nm. 
Protein was measured quantitatively by a direct fluorimetrie measurement at 278 
nm (exitation) and 340 nm (emission). The amount of protein was read from a 
calibration curve obtained with bovine serum albumin. 
Gel permeation chromatography 
Extracts of psoriatic scales (in PBS) were concentrated by vacuum evaporation, 
dialysed against PBS and subsequently applied on a Sephadex G-50 (fine grade) 
column (60 χ 1.8 cm) equilibrated with PBS. The samples were eluted with PBS 
(flow rate 0.3 ml per minute) and collected in 4 ml fractions. The fractions were 
measured for elastase inhibiting activity as described above. 
Isoelectric focusing 
Samples obtained from Sephadex G-50 chromatography were desalted by dialysis, 
concentrated in a vacuum centrifuge and applied on a 5% Polyacrylamide horizontal 
slab gel with 2% ampholines giving a linear pH gradient from 3.5 to 9.5. Running 
conditions: 1 hour at 200 V, 1 hour at 400 V. After completion of the run, lanes 
were stained with Coomassie Brilliant Blue or sliced in 1 cm portions, corresponding 
to about 0.5 pH unit per slice. The gel slices were extracted for 18 hours in 1 M 
NaCl to recover the sample components, separated on the basis of their isoelectric 
point (IEP). The gel extracts were tested for elastase inhibiting activity as indicated 
above. 
Cell culture 
Human epidermal or neonatal foreskin keratinocytes were cultured according to 
the Rheinwald-Green system as previously described.19 Second passage keratinocytes 
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were cultured to 60-70% confluence when used for extraction. Feeder cells (3T3-
fibroblasts) were removed with EDTA and trypsin and the remaining keratinocytes 
were harvested by exhaustive trypsinization19 or by scraping with a rubber police 
man. Cells were washed extensively to remove traces of fetal calf serum and 
trypsin, counted, and extracted in PBS by sonication and homogenization as de­
scribed above for biopsies and scales. This preparation was used for determination 
of inhibiting activity in cultured keratinocytes. 
Human skin fibroblasts were obtained from skin biopsies and cultured according 
to standard procedures.20 Cells were harvested by trypsinization, counted, and 
extracted as described for keratinocytes. Human umbilical vein endothelial cells (a 
kind gift of Dr. R.M.W. de Waal, Department of Pathology, University Hospital 
Nijmegen) were harvested by trypsinization and extracted as described for keratino­
cytes. 
Statistics 
Statistical evaluation was performed using the two-tailed Mann-Whitney U-test. 
P-values smaller than 0.05 were considered to be statistically significant. 
RESULTS 
Elastase inhibiting activity in normal and psoriatic epidermis 
As already shown in chapter IX, large amounts of elastase inhibiting activity were 
found in lesionai psoriatic skin and in scales from psoriatic patients. In the standard 
assay which uses 10~9 M elastase, inhibition of elastase activity was linear with 
the amount of skin or scale extract added, up to 70% inhibition as shown in Fig. 
1. The amount of epidermal extract yielding 50% inhibition was denned as 1 unit 
of inhibiting activity. Lesionai psoriatic epidermis was found to contain 116 ± 249 
units per mg tissue, (mean ± SD, η = 6) whereas normal skin contained significantly 
(p < 0.001) less activity (2.5 ± 1.4 unit per mg, η = 6). Similarly, uninvolved psoriatic 
skin contains very little inhibiting activity (1.3 ± 0.2 unit per mg, n=3) compared 
to lesionai skin (p < 0.05). Inhibiting activity could be demonstrated regardless of 
the extraction procedure or the elastase assay (either in PBS or extraction buffer 
containing high salt and detergent). This implies that inhibiting activity was not 
derived from traces of plasma in the samples, since the major plasma inhibitor of 
leukocyte elastase (alpha-1-PI) do not bind to elastase in the presence of the 
cationic detergent СТАВ (data not shown). Scales of psoriatic patients were found 
to be a particularly rich source of anti-elastase activity (1195 ± 708 units per mg, 
η = 7). Normal stratum corneum was shown to be significantly ρ < 0.001) lower in 
activity (2.6 ± 1.4 units per mg, η = 6). As for the biopsies it was found that the 
scale extracts could inhibit elastase even in the presence of 1 M NaCl and СТАВ. 
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Gel permeation chromatography 
As indicated above, psoriatic scales contain large amounts of inhibitor and since 
this material is readily available it was used as source for purification and charac­
terization of the inhibiting substances. To this end, 1 g of scales was homogenized 
in 20 ml of PBS, yielding a preparation with a specific activity of about 10000 to 
15000 units inhibitor per mg extracted (soluble) protein. The extract was centrifuged 
and the clear supernatant was concentrated and dialyscd against PBS (final volume 
1.5 ml). This sample was applied to a Sephadcx G-50 column and the amount of 
inhibiting activity in the eluent was measured as shown in Fig. 2. Two peaks of 
inhibiting activity were reproducibly found (in scales of 5 different patients) with 
K
a v
 of 0.20 and 0.41 respectively, indicating molecular weights of approximately 
20 and 10 kDalton. Both peaks contained inhibiting activity that was measurable 
in the presence of СТАВ. In order to investigate the possibility that the 20 kDalton 
species is a dimer of the 10 kDalton molecule, scales were processed and chro-
matographed in the presence of the reducing agent dithioerythritol (10 mM) 
to dissociate disulphide bonds. This, however, resulted in a total loss of the inhib-
residual elastase activitylV.) -
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Fig. 1. An extract of 500 PMN (1 ng 
elastase) was mixed with varying amounts 
of psoriatic scales extract and the 
residual elastase activity was measured. 
Typically, a linear curve is obtained up 
to 70% inhibition, both with epidermal 
and scale extract. The amount of in-
hibitor yielding 50% inhibition under 
the assay conditions was defined as 1 
unit. As can be read from the graph, 
for this particular scale extract 1 unit 
of inhibiting activity is found per 3 μ£ 
of scale. 
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Fig. 2. Elution profile of a Sephadex 
G-50 separation of psoriatic scale 
extract in PBS. Two major peaks of 
anti-elastase activity were found with 
approximate molecular weights of 20 
and 10 kDalton respectively. Solid line: 
protein concentration in the eluent, 
bars: percentage inhibition of 1 ng 
elastase by 1:50 diluted fractions. 
Vo = void volume, Vt = total column vo­
lume. Molecular weight markers: horse 
myoglobin (18.8 kD), cytochrome с (12 
kD) and aprotinine (6.5 kD). 
iting activity. When a scale extract was chromatographed under dissociating condi­
tions using a chaotropic solvent (7 M urea in PBS) to disrupt hydrogen bonds, no 
change of the elution profile (with respect to elastase inhibiting activity) was found. 
Isoelectric focusing 
The 10 kD inhibitor which was obtained in a relatively pure form from the Sephadex 
G-50 column (120 μg inhibitor per mg protein), was concentrated, desalted and 
analysed on an isoelectric focusing slab gel (non-denaturing conditions). Gel slices 
were analysed for elastase inhibiting activity; 2 peaks of activity were found at 
pH 7.3 and 9.1 (Fig. 3). It is, at present, not clear whether the inhibitor preparation 
of 10 kD is disperse with respect to IEP, or the preparation is contaminated with 
the 20 kD species and therefore displays two isoelectric points. 
Specificity and affinity of inhibiting activity 
Extracts from psoriatic lesionai skin and from psoriatic scales were tested for 
inhibiting activity against 2 other serine proteases. Both extracts from scales and 
biopsies were active against porcine pancreatic elastase irrespective of the buffer 
used (either PBS or extraction buffer). No inhibiting activity was found against 
purified PMN cathepsin G in a concentration range of 50 ng to 5 μg cathepsin G 
per ml with excess inhibitor (assuming a similar stoichiometry as for PMN elas­
tase). 
In the standard assay for anti-elastase activity a M"9 M concentration of elastase 
is used. Since the inhibition curve for crude scale extract is Unear (see Fig. 1) up 
to 70% inhibition and then becomes concave, it can be deduced that there is 
reversible binding of inhibitor and enzyme.21 Assuming an equimolar stoichiometry 
between inhibitor and enzyme, the Ki of the inhibitor(s) must be smaller than 
10"9 M,2 1 indicating a high affinity of the inhibitor for elastase. This suggests a 
functional role for the inhibitor in preventing elastase mediated damage to the 
epidermal compartment. A precise Ki measurement of the 10 and 20 kDalton in­
hibitors was not attempted, and awaits further purification of these species. 
Stability of the inhibitor 
The inhibiting activity of crude scale extracts was shown to be acid- and alkaline-
stable. Incubation for 30 minutes in 0.1 N HCl or 0.1 N NaOH did not reduce the 
inhibiting activity. Inhibiting activity was relatively heat-stable, the half-life of 
enzyme activity at 950C being about 15 minutes. All inhibiting activity was lost in 
the presence of the reducing agent dithioerythritol (10 mM). 
Source of the inhibitor 
Since normal epidermis comprises several cell types such as keratinocytes, melano­
cytes and Langerhans cells, and in the psoriatic patient infiltrating inflammatory 
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cells such as PMN and Τ lymphocytes are present as well, the actual source of 
the anti-elastase activity is not known. In addition, in biopsies also small amounts 
of connective tissue (containing fibroblasts and capillary endothelium) can be present. 
It was found that mononuclear cells purified from peripheral blood do not exhibit 
anti-elastase activity. Similarly, in a fractioned PMN extract no anti-elastase 
activity could be demonstrated (J.A. Kramps, personal communication). These findings 
rule out the possibility that inflammatory cells themselves deposit the inhibitor 
activity in the epidermis. Large amounts of anti-elastase activity were, however, 
found in cultured human keratinocytes (derived either from neonatal foreskin or 
adult human epidermis), as shown in Fig. 4. The presence of inhibitor was specific 
in the sense that cultured human skin fibroblasts and human umbilical vein endo­
thelial cells were negative for anti-elastase activity (up to 20,000 cells tested in 
the assay). 
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Fig. 3. The 10 kD fraction of psoriatic 
scale extract purified on Sephadex G-50 
was subjected to isoelectric focusing 
(pH gradient 3.5 to 9.5). Gelslices were 
extracted with 1 M NaCl and measured 
for elastase inhibiting activity. Two 
peaks of activity were found at iso-
electric point 7.3 and 9.1. 
Fig. 4. Elastase inhibiting activity was 
measured in extracts of 3 types of 
cultured cells: human foreskin kera-
tinocytes, human skin fibroblasts and 
human umbilical vein endothelial cells. 
Only keratinocytes were shown to 
contain significant amounts of inhibitor 
(1 unit per 2000 cells), whereas the 
other cell types were practically devoid 
of inhibiting activity (up to 20.000 
cells tested in the assay). Vertical 
axis: the residual activity of 1 ng 
elastase; horizontal axis: the number 
of cells added in the assay. 
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DISCUSSION 
We have partially characterized the elastase inhibiting activity in psoriatic epidermis 
and show that it is associated with at least two proteins of about 10 and 20 
kDalton. These species exhibit a high affinity binding of elastase and display a 
narrow specificity since human cathepsin G is not affected, whereas most other 
known elastase inhibitors are also active against this protease. Keratinocytes are 
probably the major source of inhibiting activity. 
Proteolytic enzymes catalyze the hydrolysis of peptide bonds and the possible roles 
of these enzymes in physiological and pathological processes are numerous.11 The 
normal catabolism of intracellular and extracellular proteins is controlled by various 
proteases that either act within the lysosomal compartment or in the extracellular 
space. Activation of the complement system, blood clotting and fibrinolysis is tightly 
controlled by proteolytic enzymes and their inhibitors. During inflammatory pro-
cesses proteolytic enzymes promote the generation of chemotactic peptides and 
the increase of vascular permeability, and contribute to degradation of structural 
proteins, detachment of cells and possibly cell death. In order to control unwanted, 
excessive proteolysis, a large amount of proteinase inhibitors of various specificities 
are present in plasma. Quantitatively the most important proteinase inhibitors are 
alpha-2-macroglobulin which inhibits all classes of proteases, and alpha-1-PI which 
inhibits many serine proteases although its physiologic function is probably directed 
against PMN elastase and cathepsin G.22 Depending on their molecular weight and 
isoelectric point these proteinase inhibitors are also present in the interstitial 
fluid, mucous secretions and avascular compartments such as cartilage and epidermis. 
Since basal membranes act as a selective barrier for high molecular weight anionic 
substances, the concentration of alpha-2-macroglobulin and possibly alpha-1-PI will 
be accordingly lower in the epidermis compared to plasma or connective tissue. 
Alpha-1-PI was shown to be present in human skin but the concentration of alpha-
2-macroglobulin is extremely low.a Apart from systemic proteinase inhibitors, a 
number of locally synthesized inhibitors2·23 are known such as antileukoprotease 
(ALP) in lungs ( = secretory leukocyte protease inhibitor (SLPI) in parotid secre-
tions). In skin, several proteases and proteinase inhibitors have been identified.11 
Proteases of 'all classes are found in skin, including several serine proteases that 
degrade casein, kininogen and synthetic substrates with specificity for trypsin and 
chymotrypsin, metalloproteases that degrade collagen and gelatin, cathepsin B, 
cathepsin D and various exopeptidases. The exact source of these enzymes is 
uncertain in many cases, although for some enzymes the exact localization could 
be estabhshed. Basal keratmocytes have been shown to contain cathepsin D 1 1 , and 
skin mast cells are known to contain trypsinlike24 and chymotrypsinlike activity. 
The exact function of cutaneous proteases is in many cases not known. It was, 
however, recently demonstrated that keratinocyte proteases are involved in the 
processing of profilaggrin.25 Similarly, cell shedding from human plantar skin was 
shown to be dependent on endogenous neutral protease activity.20 Several skin 
specific proteinase inhibitors have been reported including inhibitors of human 
skin cystein proteases27, a papain inhibitor purified from psoriatic scales which 
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was shown to be present in spinous cells and hair follicles9, and a broad spectrum 
proteinase inhibitor present in normal human epidermis.10 
Recently it was shown that human PMN elastase and cathepsin G can degrade 
the epidermal-dermal junction of human skin in vitro0, suggesting that blister 
formation as seen in various diseases can be mediated by these serine proteases. 
Since extensive infiltration of the epidermis with PMN and formation of micro-
abscesses2* is one of the hallmarks of an active psoriatic lesion, we investigated 
the protective potential of human epidermis against PMN derived proteases. Anti-
elastase activity was found to be present in psoriatic lesions and could also be 
induced by standard injury (tape-stripping) of normal skin (as shown in chapter 
II). We therefore concluded that production of elastase inhibitors was induced by 
the inflammatory reaction, although the exact kinetics of the process are yet 
unknown. In human skin no elastase inhibitor has been described so far, except 
for alpha- l-PIe which is clearly different from the inhibitor we described. The 
inhibitor reported in this paper show similarity to a specific elastase inhibitor 
found in human bronchial secretions29, which does not inhibit cathepsin G. However, 
this inhibitor has a lower molecular weight (S kDalton for the monomer), it is not 
inhibited by reducing agent and the dimer is dissociable in 7 M urea. Further 
purification and characterization of the epidermal elastase inhibitors is required to 
obtain information on their precise identity. 
The inhibitor was found to be present in inflammatory conditions (see also chapter 
IX or could be induced by experimental inflammation (chapter II). However, these 
conditions are also characterized by epidermal hyperproliferation as measured by 
recruitment of Go-cells from the basal layer and a high percentage of cells in S-
phase.3 0 ·3 1 An alternative explanation for the induction of anti-elastase activity is 
that it is specific for proliferating epidermal cells. The specificity of the inhibitor 
could be primarily directed against a hitherto unknown protease involved in cell 
proliferation. Indeed, many proteases were suggested to be involved in cell proli-
feration in vitro and tumor malignancy in vivo.32 The epidermal anti-elastase 
activity could in this case be coincidental, as a more epiphenomenon. Our data 
showing that cultured keratinocytes produce large amounts of anti-elastase activity 
support this contention. Keratinocytes cultured in vitro are hyperproliferative in a 
sense that there is no resting (Go) population, nearly all cells are cycling and 
expressing keratin 16 3 3 thereby resembling the situation in psoriasis.34 In addition, 
there are no inflammatory cells present in cell culture, the only cell types being 
the keratinocytes themselves and the 3T3 fibroblasts which act as feeder cells. 
The exact relationship between inhibitor production, inflammation and cell prolife-
ration is currently being investigated. This will provide us with basic knowledge 
on the processes of epidermal inflammation and hyperproliferation, and might 
contribute to our understanding of the pathophysiological mechanisms in inflam-
matory skin diseases. 
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Chapter XI 
General discussion 
1 RELEVANCE OF IN VIVO MODELS 
In psoriasis diverse genetic, local and systemic abnormalities combine to express 
the three main characteristics of the disease: epidermal hyperproliferation, intra-
epidermal accumulation of polymorphonuclear leukocytes (PMN), and abnormal 
keratinization. Ultimately, no doubt, the etiopathogenesis of psoriasis will be studied 
molecularly, in vitro, at the gene level, and suitable animal systems will be devel-
oped to test the therapeutic value of new drugs or treatments. Today, because 
psoriasis has so far not been found in animals, test models are often based on 
systems that possess or have acquired one or more of the characteristics of the 
disease. The value of these experiments rests in the hope that effective therapy 
of a model symptom will be paralleled by a therapeutic effect on the psoriatic 
lesion. More specifically, the value of the in vivo LTB* and stripping models which 
we used in our experiments, rests on the observation that all systemic and local 
antipsoriatic therapies interfere with the transepidermal migration of PMN (chapters 
III-VI). Our models, therefore, are highly relevant in the testing of new anti-
psoriatic drugs. 
The role of the migration and accumulation of PMN in the pathogenesis of psoriasis 
is still questioned. Some authors believe it to be a primary event of the disease,1·2 
while some more recent data suggest that PMN migration may be an intermediary 
step.3 Despite this controversy, inflammation remains an early pathogenetic event 
and a characteristic feature of psoriatic lesions. Recently, interest has centred on 
the role of arachidonic acid (AA) and its metabolites in the pathogenesis of psoria-
sis.4 However, if any are of primary importance in psoriasis remains unproven. 
From our results and data in the literature we have developed a model for the 
transepidermal migration of PMN in the skin. Within this model (Fig. 1) we discuss 
the possible action site of different antipsoriatic therapies and indicate system 
components that may be abnormal in psoriasis. 
2 MIGRATION OF PMN IN NORMAL SKIN 
2.1 In vivo models 
Inflammation is preceded by the release of mediators of inflammation (Fig. 2), 
including the metabolites of arachidonic acid (AA): the hydroxyeicosatetraenoic 
acids (HETEs), leukotrienes (LT) and prostaglandins (PG). Mediators of inflammation 
are released by the epidermis following trauma. After 2 h PMN are visible in the 
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f ^* "endothelial gate control' 
Fig. 1. Schematic presentation of dermal and epidermal 'controls' of PMN migration. 
(a) Chentoattractants attracting (+) the PMN and thus causing inflammation; (b) 
PMN migration from capillary into dermis and epidermis where the PMN promote 
epidermal hyperproliferation and cause microabscesses surrounded by abnormal 
keratinization; (c) mediators of inflammation (15-HETE, PGE2) and (d) cytochrome 
P-450 inhibit (-) chemoattraction; (e) elastase inhibitor prevents (-) PMN penetra-
tion and thus inflammation by action at various levels; (f) endothelial gate control 
prevents (-) the PMN from leaving the capillary, either by itself or in cooperation 
with the elastase inhibitor. 
epidermis,5 where they reach maximum accumulation after 8 h (chapter II), This 
early recruitment of PMN at the site of inflammation is followed by infiltration of 
mononuclear leukocytes.0 Some 40 h after the penetration of PMN epidermal hyper-
proliferation occurs as increased recruitment of cycling cells.7·3 Abnormal keratin-
ization (parakeratosis) is observed during the first 42 h after trauma.9 In the 
absence of a control mechanism an inflammation would be amplified and perpetuated 
by the significant amounts of LTB«* generated by PMN; the homeostatic control 
mechanisms which terminate PMN migration we term tachyphylaxis. 
Tachyphylaxis may be elicited by repeated topical application of a chemoattractant 
to intact skin. A single application of LTB* or 12-HETE produces PMN micro-
abscesses at 24 h which are resolving at 48 h following apphcation. In contrast, 
multiple applications of LTB* or 12-HETE at the same site cause local tachyphylaxis 
with respect to visible inflammatory and histological changes.10"12 Thus, at the 
site of repeated applications PMN microabscess formation is significantly reduced, 
while a single application at the adjacent site elicits normal amounts of PMN 
microabscesses. 
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2.2 Tachyphylaxis 
Potential candidates for tachyphylaxis in skin would cause a down-regulation of 
PMN migration in various ways: 
2.2.1 Mediators of inflammation with inhibiting properties 
15-HETE, a 15-lipoxygenase product of AA, is known to inhibit the formation of 
epidermal 12-ΉΕΤΕ,13 LTB.*14 and the effect of LTB4 on PMN Chemotaxis
15
 and 
inflammatory skin response.16 It may originate in the dermis,13 epidermis and 
perhaps the infiltrating PMN.17 Another possibility is PGEz which in animal mod­
els1 8 reduces skin infiltration of PMN in LTB4-mduced inflammation. 
2.2.2 Cytochrome Poso 
This system degrades mediators of inflammation. In rats LTB-* is degraded via a 
hepatic cytochrome P4so-linked oxidation19 and enzymes of this pathway are also 
inducible in human skin.20 Intracellular metabolism of LTB* occurs mainly via the 
ω-oxidation pathway and produces 20 OH-LTB* and 20 COOH-LTB*, which are less 
active than LTB.*.21 Perhaps the enzyme necessary for ω-oxidation is induced by 
skin injury or topical apphcation of LTB* and may work by an analogous cutaneous 
cytochrome P^o-linked oxidation system for degradation of inflammation mediators. 
87 
2.2.3 Endothelial gate control 
In cases of acute inflammation the physiological interactions between circulating 
PMN and vascular endotheUum are dramatically altered and subjected to homeostatic 
control. The basic events in PMN-endothelial interactions during acute inflammation 
have been established from elegant in vivo observations: adherence, diapedesis and 
extravascular migration.22·23 In vitro studies demonstrate the relative importance 
of the PMN or endothelial cell, since isolated PMN and endothelial cells can be 
manipulated individually. Many biological substances increase PMN adherence to 
cultured endotheUum including products of complement activation, chemotactic 
peptides,24 platelet products,25 lipoxygenase products2*-27 such as LTB*2 8 ·2 9 and 
neuraminidase treatments.30 On the other hand, prostacyclin (PGI2) decreases PMN 
adherence to endothelial cells.30 Glycoproteins on the membrane of the PMN3 1 
and endothelial cells32 play a critical role in PMN-endothelial interaction and may 
function as receptor. Recent observations indicate that endothelium can generate 
mediators such as platelet-activating factor (PAF),3 3 ·3 4 a potent PMN activating 
agent and factors with chemotactic activity.35"37 The only major concern in these 
studies is that the endothelium may behave differently in the culture system. We 
speculate that PMN adhesiveness can be controlled locally by the endothelium and 
we therefore introduce the term "endothelial gate control" as a possible tachy-
phylaxis mechanism at this level (Fig. 1). 
2.2.4 PMN elastase inhibitory 
The enzyme elastase and its inhibitors may provide yet another regulation mecha-
nism for tachyphylaxis. Elastase facilitates the penetration of PMN into the skin 
by mediating endothelial cell detachment38 and degrading the basement membrane.30 
Inhibition of elastase activity prevents endothelial cell detachment and the degra-
dation of the basement membrane and thus inhibits PMN invasion. 
3 MIGRATION OF PMN IN PSORIATIC SKIN 
3.1 In vivo models 
3.1.1 LTBa-induced accumulation of PMN 
A number of observations suggest that in psoriatic skin there is a shift in 
cutaneous homeostasis. Normal skin shows a heavy PMN infiltrate following an 
initial application of LTB«, but the response diminishes markedly if repeated doses 
are appüed to the same site.12 In clinically uninvolved psoriatic skin (which con-
tains raised levels of endogenous LTB«), the initial response is already much less 
than in normal skin.12 ·40 In the psoriatic lesion, where there is massive overpro-
duction of AA metabohtes including LTB*,41 application of additional LTB* fails 
to induce penetration of PMN into the lesion.42 It is clear that in all situations, 
there is an inverse relationship between the concentration of LTB« to which the 
skin has been exposed and the responsiveness of the skin to experimental applica-
tion of this mediator. 
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3.1.2 Trauma-induced accumulation of PMN 
A shift in cutaneous homeostasis is also observed in this model. When non-lesional 
psoriatic skin and normal controls are injured by a standardized approach of 
sellotape stripping, PMN infiltration is of the same order of magnitude in both. 
Thus, the integrated process by which mediators of inflammation are released and 
PMN accumulate, seems to be in balance. In unstable psoriatics, however, the 
response to injury is significantly higher than in stable psoriatics, indicating that 
in the former the system is out of balance (chapter II). 
3.2 The psoriatic lesion 
3.2.1 Release of arachidonic acid metabolites 
Psoriatic skin may be lesionai or of clinically normal appearance (non-lesional/un-
involved). The observed abnormalities occur at different levels of inflammation 
control. At the molecular level arachidonic acid (AA) metabolism is abnormal in 
psoriasis (Fig. 2). Homogenates of psoriatic epidermis (lesionai and non-lesional) 
have elevated amounts of the rate-limiting and Ca dependent enzyme phospholipase 
Aa (PLAa),-*3·** which may explain why psoriatic skin contains elevated amounts 
of free AA and its metaboUtes, LTB*, 12-HETE and PGEz. 
3.2.2 Dynamics of PMN migration 
At a lesion there seems to be a changing balance between factors that normalize 
homeostasis and those that trigger or exacerbate, cause remission or perpetuation 
of the condition. Depending in which direction this balance tilts, lesions may 
appear, disappear or stabilize (chapter I, Fig. 1). In the early stages of an active 
psoriatic lesion, PMN migration and accumulation is massive,1·2 but in chronic 
stable plaque psoriasis PMN are scanty and restricted to PMN islands or "hot 
spots".45 This indicates that in stable plaque psoriasis mechanisms of tachyphylaxis 
are active, causing a temporary down-regulation of inflammation. 
3.2.3 PMN migration and epidermal growth 
Epidermal hyperproliferation is a critical pathological feature of psoriasis and it 
is therefore important to establish its relationship to inflammation and maturation 
of the psoriatic epidermis. We observed that in the marginal zone of the psoriatic 
lesion proliferation occurs after PMN invasion (chapter VIII). This agrees with Braun-
Falco,40 who reported that inflammatory changes precede epidermal proliferation 
and differentiation. Further at the molecular level epidermal growth control and 
production of chemotactic factors are linked; both LTB* and 12-HETE are potent 
stimulants of epidermal growth and powerful chemoattractants for PMN.4 ·47 ·4* 
3.2.4 Tachyphylaxis 
The four possible mechanisms of tachyphylaxis in normal skin have been described 
above (Fig 1). Breakdown in any one of them may be an important factor in the 
maintenance of the psoriatic condition. Thus, uninvolved psoriatic skin in vitro 
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produces less 15-HETE than normal dermis.49 A shortage of 15-HETE in the dermis 
may result in a shortage of 15-HETE in the epidermis, thereby allowing excessive 
5- and 12-lipoxygenase activities in the psoriatic epidermis. In support of this 
hypothesis is the observation that in most patients injections of 15-HETE into the 
psoriatic plaques causes clinical regression of the lesion.50 
In the cytochrome P^so system the enzyme aryl hydrocarbon hydroxylase that is 
induced in vitro by benzanthracene, has been shown to have enhanced inducibihty 
in psoriatic epidermis compared to normal epidermis.20 Since LTB* is degraded by 
a cytochrome P^so-linked oxidation, enhanced enzymes of this pathway may help 
in the regression of psoriasis. 
The elastase inhibitor found in the psoriatic lesion is probably different from any 
previously described antiprotease. It is present in large amounts in lesions and 
scales, but in negligible amounts in normal and non-lesional psoriatic skin (chapters 
IX and X). The source of this inhibitor seems to be the proliferating keratinocytes, 
but what stimulus or stimuli trigger its production is unknown. Elevated amounts 
of the inhibitor are also found in other dermatoses with marked epidermal PMN 
infiltration (chapter IX) or in experimental inflammation (chapter II). Considering 
the inhibitor's low molecular weight and its cationic nature, we suppose it can pass 
the basement membrane51 and there prevent penetration of PMN into the psoriatic 
lesion. Since the inhibitor is also found in disorders of keratinization and/or 
hyperproliferation (chapter IX), production of the elastase inhibitor may represent 
an off-switch mechanism in the local inflammatory response and/or may be involved 
in the regulation of epidermal hyperproliferation and keratinization. 
4 ANTIPSORIATIC THERAPIES AND PMN MIGRATION 
4.1 General aspects 
Elements of the mechanisms of tachyphylaxis are depicted in Fig. 1. We find that 
systemic (acitretin) and local antipsoriatic therapies (corticosteroids, dithranol, 
PUVA, UVB) in therapeutic doses interfere with the transepidermal migration of 
PMN (chapter III-VI). From the viewpoint of PMN migration they act in the same 
direction as the tachyphylaxis phenomenon. It is not known if this is a direct 
effect on PMN Chemotaxis, or a mechanism that reinforces tachyphylaxis. 
4.2 Interference with PMN Chemotaxis 
PMN Chemotaxis may be suppressed (directly or indirectly) in a number of ways. 
Circulating PMN may be inhibited directly by PUVA, UVB, dithranol, corticosteroids, 
methotrexate,52 or retinoids.53 
Chemoattractants may also be the action site for corticosteroids, dithranol, reti-
noids, PUVA or UVB. Thus, when the corticosteroid clobetasol propionate is topi-
cally applied for 3 days to lesionai skin, lower levels of LTB« and AA are found 
in chamber fluid analysis compared to vehicle treated controls.5"* We observed 
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(chapter III) that there is reduced accumulation of PMN in normal skin, 2 days 
after corticosteroid treatment. These results are in agreement with the proposed 
anti-phosphoUpase Az action of glucocorticosteroids.53·50 The action site for 
dithranol is less clear. In vitro it inhibits formation of LTB4 and IZ-HETE. 3" 7 · 5 0 
However, at lower concentrations the inactivation of LTB* does not take p lace . 5 7 · 5 8 
Thus, topical application of 0.25% dithranol for 10 days on patients with chronic 
plaque psoriasis results in improvement of the condition, concurrently with reduction 
in chamber fluid samples of AA level, but not of 12-HETE or LTB4. 5 0 Perhaps at 
higher in vivo concentrations of dithranol the Upoxygenase pathway may also be 
the direct antipsoriatic target. Oral administration of 50 mg per day etretinate for 
35 days causes a gradual lowering of AA and 12-HETE, in chamber fluid samples, 
but not of LTB4, indicating that retinoids have a selective inhibitory effect on 
the AA metabolism.60 
Besides interference with AA derived chemoattractants, other classes of chemotactic 
agents may be affected by the therapeutic agents. PUVA inactivates the complement 
split product Gsa in vitro 0 1 and the chemotactic activity of psoriasis leukotactic 
factor (PLF) is inhibited following in vivo treatment of psoriatic lesions with 
PUVA. 0 2 UVB irradiation of mice results in the induction of an inhibitor of the 
chemoattractant interleukin l . e 3 
4.3 Tachyphylaxis 
Antipsoriatic therapies may exert their beneficial effect by reinforcing the mecha­
nism of tachyphylaxis in a number of ways. 
Thus UVB, PUVA, dithranol therapies may induce mediators which counteract 
inflammation (Fig. 1). For example, UVB irradiation stimulates the AA cascade, as 
indicated by the increased levels of PGE2 and 12-HETE 6 4 found in UVB irradiated 
skin. Similarly, a single apphcation of 3% dithranol to non-lesional skin of psoriatics 
induces raised PGE2 levels in suction bullae exudate.6 4 
Cytochrome P^so-dependent enzyme activity is already present in psoriatic skin 2 0 
and may enhance the inactivation of LTB* via the ω-oxidation pathway.21 Therapies 
with t a r 6 5 - 6 7 and U V B 6 7 are inducers of cutaneous cytochrome P450 enzymes and 
may thereforfe reinforce the tachyphylaxis in this way. 
In vitro corticosteroids inhibit PMN adhesion to endothelial cells.68 They act partly 
by inhibiting the formation of LTB* necessary for increased adhesion of PMN to 
the cell wall.69 Since treatment with PUVA, U V B 7 0 and possibly dithranol may 
cause vascular damage it seems that at the "endothelial gate" a mechanism of 
tachyphylaxis that limits vascular damage may exist. 
In the psoriatic lesion, non-lesional skin, or in normal skin, elastase inhibiting 
activity is not influenced by antipsoriatic therapies (chapters III-VI). Therefore, it 
is unlikely that this tachyphylaxis mechanism is induced by the antipsoriatic thera­
pies. 
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5 PROSPECTS 
Therapy prospects are clearly linked to advances in basic research. The various 
unknowns noted in the discussion suggest several lines for future dermatologjcal 
research in this field. Particularly exciting may prove to be research into the 
physiological role of the elastase inhibitor(s) we have discovered in psoriatic lesions. 
The inhibitor should be purified and immunohistochemically localized on skin sec­
tions of diverse inflammatory and/or proliferating skin disorders, with monoclonal 
antibodies. 
Other exciting lines of future research include the unraveling of the nature of 
the "endothelial gate control", evaluation of the cutaneous cytochrome P450 system 
and the metabolism of eicosanoids products, especially 15-HETE. 
Pharmacological manipulation of these metabolic systems might yield into new 
therapies for patients with psoriasis. 
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Summary 
Chapter I. The aim of this thesis is to improve our understanding of the trans-
epidermal migration of polymorphonuclear leukocytes (PMN) in psoriasis and the 
effect of antipsoriatic therapies on their migration. In vivo PMN migration in the 
skin is induced by: 1) locally applying to the skin the chemoattractant leukotriene 
Вл (LTEU); 2) chemoattractants released as a result of trauma to the skin following 
sellotape stripping. The PMN are quantified by measuring fluorometrically the 
marker enzyme elastase in skin homogenates. 
In chapter II PMN accumulation is measured at various time intervals in injured 
non-lesional psoriatic skin and in normal skin. There is no difference in the re­
sponse of the process between the normal controls and the psoriatic patients. 
However, if unstable and stable psoriatics are compared, there is increased PMN 
migration in the unstable patients. We also find that following trauma of both 
non-lesional psoriatic skin and normal skin, an inhibitor of PMN elastase is induced. 
This inhibitor appears in the injured skin after PMN penetration. 
In chapter ΙΠ the effect of topical corticosteroids on PMN migration in normal 
skin is studied. It is found that LTB«- or trauma-induced PMN migration is inhibited 
by corticosteroids after 2 days. The inhibition effect could not be shown after 14 
days of treatment. 
In chapter IV results are presented of the effect of topical apphcation of dithranol 
with and without 2% salicylic acid on "in situ Chemotaxis" of PMN. It is shown 
that dithranol with or without salicylic acid inhibits PMN migration when induced 
by LTBa but not when induced by trauma. The presence of salicylic acid does not 
increase the inhibiting potential of dithranol. Similarly in chapter V the effect of 
light treatments UVB and PUVA are shown to be very effective inhibitors of 
trauma- and LTB4-induced PMN accumulation in normal skin. 
In chapter VI patients with persistent palmoplantar pustulosis (PPP) are sys-
temically treated with acitretin. It is found that LTB^-induced PMN are inhibited 
in a dose-related way in non-lesional skin. 
In chapter VII the effect of systemic treatment with tetracychne is examined. 
This is not a standard therapy for chronic plaque psoriasis and we find that 1 g 
tetracycline per day for 10 days does not inhibit either LTB4- or trauma-induced 
PMN in normal skin. 
In chapter VIII the histological relationship is examined between epidermal hyper-
proliferation and PMN migration in the marginal zone of chronic plaque psoriasis 
lesions. We find a positive correlation between the number of КІ67 nucleus-positive 
cells (an immunohistochemical marker for epidermal hyperproliferation) and the 
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number of Munro microabscesses observed after haematoxylin-eosin staining. Where 
PMN penetrate the epidermis, micropustules of Kogoj are formed, and the concen-
tration of Ki67 nucleus-positive cells is clearly less than at the locations where 
microabscesses are formed. These results indicate a link between PMN infiltration 
and epidermal hyperproliferation, and that hyperproliferation follows the penetration 
of PMN in the epidermis. 
In chapter IX the possibility of a relationship between the elastase inhibitor and 
inflammation is examined. Scales taken from conditions that lack infiltrate cells 
(X-linked recessive ichthyosis, X-linked dominant chondrodysplasia punctata, non-
erythrodermic autosomal recessive lamellar ichthyosis) and from conditions with 
primarily mononuclear infiltrate (atopic dermatitis) show moderate increases in 
elastase inhibitmg activity compared to normal stratum corneum. Scales taken from 
conditions with mixed infiltrates of PMN and mononuclear infiltrates (psoriasis, 
Netherton syndrome, erythrodermic autosomal recessive lamellar ichthyosis) have a 
more marked increase in elastase inhibiting activity. The results suggest that 
elastase inhibitmg activity is a clear indicator of abnormal keratinization especially 
when a mixed infiltrate is present in the skin. 
In chapter X the preliminary biochemical characterization of the PMN elastase 
inhibitor(s) is given. This inhibitor is found in large amounts in psoriasis lesions 
and scales, and is almost absent in normal skin, uninvolved skin of psoriatics or 
in normal stratum corneum. The inhibitor reacts stoichiometrically with human 
PMN elastase. It inhibits porcbe pancreatic elastase but not human cathepsin G. 
It is pH stable, relatively heat stable and column chromatography indicate molecular 
weights of 10 kD and 20 kD. It is, apparently, produced by proliferating keratino-
cytes. 
Finally, in chapter XI, our results and data in the Uterature are used to construct 
a model that may explain the relationship between PMN migration and various 
therapeutic modalities. It is concluded that in vivo clinical models for PMN induc-
tion are valuable in the testing of new antipsoriatic treatments. 
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Samenvatting 
Hoofdstuk I. De doelstelling van dit proefschrift is een beter inzicht te verkrijgen 
in de transepidennale migratie van polymorfkernigc granulocyten (PMN) bij psoriasis 
en in de relatie van anti-psoriatische therapieën met deze migratie. De migratie van 
PMN is bestudeerd in twee in vivo modellen: 
1) het leukotriene B.» (LTB*) model, waarbij het chemoattractans LTB<* lokaal op 
de huid wordt geappliceerd en 
2) het sellotape strip model, waarbij de huid getraumatiseerd wordt en chemoattrac-
tantia vrijkomen. 
Met behulp van een fluorometrische meting van het PMN specifieke enzym elastase 
kunnen PMN in huidinfiltraten worden gekwantificeerd. 
In hoofdstuk II wordt na het traumatiseren van de klinisch normale huid van chroni-
sche plaque psoriasis patiënten de reactie van de PMN in de tijd bestudeerd. Er 
blijkt geen verschil te bestaan in de PMN reactie van de psoriasis patiënt vergeleken 
met gezonde vrijwilligers. Bij onstabiele psoriasis patiënten is er echter een ver-
hoogde migratie van PMN in de huid vergeleken met de stabiele psoriasis patiënt. 
Verder blijkt dat door het traumatiseren van de huid bij psoriasis patiënten en 
vrijwilligers, een remmer van het enzym elastase geïnduceerd wordt, die in de 
huid verschijnt na het penetreren van de PMN in de epidermis. 
Hoofdstuk III behandelt het effect van lokale behandeling met clobetasol-17-pro-
pionaat op migratie van PMN in de huid van normale proefpersonen, geïnduceerd 
door lokale applicatie met LTB.* of na het strippen met sellotape. Clobetasol-17-
propionaat in therapeutische doseringen blijkt in beide in vivo modellen na 2 dagen 
de migratie van PMN in de huid te remmen; na 14 dagen behandeling is het rem-
mend effect niet meer aanwezig. 
In hoofdstuk IV wordt nagegaan wat het effect is van lokale behandelingen met 
dithranol, met of zonder toevoeging van salicylzuur op de "in situ Chemotaxis" van 
PMN. Aangetoond wordt dat dithranol een remmend effect heeft op de migratie 
van PMN na het opbrengen van LTB*, doch geen effect heeft op de "in situ Chemo-
taxis" van PMN na het strippen. Het toevoegen van 2% salicylzuur heeft geen 
versterkend effect op de remmende werking van dithranol. 
Hoofdstuk V behandelt een soortgelijk onderzoek van lokale behandelingen met 
lichttherapieën bij normale controles. Zowel ultraviolet В (UVB) als topisch psora-
leen en ultraviolet A (PUVA) veroorzaken een aanzienlijke remming van de trauma-
en LTB^-geïnduceerde PMN accumulatie. 
Hoofdstuk VI rapporteert het remmend effect van systemische behandeling met 
acitretm op de door LTB^-geïnduceerde migratie in de klinisch normale huid van 
patiënten met een persisterende pustulosis van handen en voeten (PPP). Dit effect 
blijkt dosis-afhankelijk te zijn. 
Hoofdstuk VII beschrijft een onderzoek naar het effect van systemische behandeling 
met tetracycline op de trauma- en LTB^-gemduceerde migratie van PMN in de 
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huid bij normale vrijwilligers. Tetracycline is geen gangbare therapie bij de behan-
deling van chronische plaque psoriasis. Uit ons onderzoek blijkt, dat tetracycline 
gedurende 10 dagen in een dosering van 1 gram per dag geen effect heeft op de 
LTB4- en trauma-geïnduceerde "Chemotaxis" van PMN. 
Hoofdstuk VIII is een histologische studie naar de relatie tussen epidermale hyper-
proliferatie en PMN migratie in de randzone van chronische plaque psoriasis lesies. 
Er wordt een positieve correlatie gevonden tussen het aantal КІ67 nucleus-positieve 
cellen (immunohistochemische "marker" voor epidermale hyperproliferatie) en het 
aantal Munro microabcessen (haematoxyline-eosine kleuring). Op plaatsen waar 
PMN de epidermis penetreren en micropustels van Kogoj vormen, is de dichtheid 
van КІ67 nucleus-positieve cellen duidelijk minder dan bij plaatsen met microabces-
vorming. Deze resultaten suggereren, dat er een verband bestaat tussen PMN in­
filtratie en epidermale hyperproliferatie en dat hyperproliferatie volgt na het 
penetreren van PMN in de epidermis. 
In hoofdstuk IX wordt nagegaan of er een verband bestaat tussen de elastase-
remmende activiteit en inflammatie. Aangetoond wordt, dat zowel schilfers van 
keratinisatiestoornissen zonder infiltraatcellen (X-gebonden recessieve ichthyosis, 
X-gebonden dominante chondrodysplasia punctata, niet-erythrodermische autosomale 
recessieve lamellaire ichthyosis) als van dermatosen met een voornamelijk mono-
nucleair infiltraat (atopische dermatitis) een matig verhoogde elastase-remmende 
activiteit hebben vergeleken met normaal stratum corneum. Schilfers van dermatosen 
met een gemengd infiltraat van PMN en mononucleairen zoals psoriasis, Netherton 
syndroom en erythrodermische autosomale recessieve lamellaire ichthyosis hebben 
daarentegen een sterk verhoogde elastase-remmende activiteit. De resultaten sug­
gereren dat de elastase-remmende activiteit een indicator is voor abnormale kera-
tinisatie, met een duidelijke expressie wanneer er een gemengd infiltraat aanwezig 
is in de huid. 
Hoofdstuk X geeft een eerste aanzet tot de biochemische karakterisering van de 
remnier(s) van PMN elastase, die in grote hoeveelheden in psoriasis lesies en 
schilfers voorkom(t)(en). Deze remmer is nauwelijks aanwezig in de niet-aangedane 
huid van psoriasis patiënten, in de normale huid of in normaal stratum corneum. 
De remmer reageert stoichiometrisch met humaan PMN elastase en blijkt varkens 
pancreas elastase ook te remmen. Humaan PMN cathepsine G wordt daarentegen niet 
geremd. De elastase remmer is pH stabiel, relatief hittestabiel en met kolomchroma-
tografie worden molecuulgewichten van 10 kD en 20 kD gevonden. In vitro expe-
rimenten geven aan, dat de remmer een product is van proliferende keratinocyten. 
In hoofdstuk XI zijn onze resultaten en de gegevens uit de literatuur gebruikt om 
een theoretisch model te construeren. Dit model zou een verklaring kunnen geven 
voor de relatie tussen PMN migratie en de verschillende therapieën. Wij concluderen 
dat onze klinische in vivo modellen relevant zijn in het testen van nieuwe anti-
psoriatische behandelingen. 
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STELLINGEN 
I 
Het leukotriene В* (LTB-t) model en het sellotape stripmodel zijn bruikbaar voor 
het testen van experimentele therapieën op een antipsoriatisch effect. 
Dit proefschrift, hoofdstukken I en XI. 
II 
In de randzone van psoriasis laesies volgt epidermale hyperproliferatie op het 
penetreren van polymorfkemige granulocyten in de epidermis. 
Dit proefschrift, hoofdstuk VIII. 
III 
Het bevestigen van de hypothese dat de produktie van anti-elastase remmende 
activiteit door de humane keratinocyt een 'switch off mechanisme voor de lokale 
inflammatie is, kan leiden tot de ontwikkeling van een nieuwe generatie ontste-
kingsremmende pharmaca. 
Dit proefschrift, hoofdstukken II, IX, X, XI. 
IV 
Indien dermatologische tijdschriften de voorkeur gaven aan langere, veelomvattende 
artikelen boven korte publikaties zou dit ten goede komen aan de kwaliteit van 
deze wetenschappelijke literatuur. 
V 
Wie vette vis(olie) verorbert zal er wel van lusten. 
Isseroff RR. Fish again for dinnerl The role of fish and other dietary oils in 
the therapy of skin disease. J Am Acad Dermatol 1988; 19: 107340. 
JJE van Everdingen. Nog meer (over) visolie bij psoriasis. Ned Tijdschr Geneesk 
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